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 ‘If we were to name the most powerful assumption of all, which leads one on and on 
in an attempt to understand life, it is that all things are made of atoms, and that 
everything that living things do can be understood in terms of the jigglings and 
wigglings of atoms.’  
Richard Feynman, Nobel Prize in Physics 1965 
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1 INTRODUCTION  
 
The most important issue in Medicinal Chemistry is without any doubt the drug 
design part, often referred to as rational drug design or simply rational design. It 
represents the process of finding new drugs based on the knowledge of a biological 
target or all the biochemical steps in which the target is involved [1]. Most 
commonly, The aim of a drug discovery process is to find an organic small molecule 
responsible for modulating the biochemical patterns of a cell process. The activation 
or inhibition of a biomolecule function, such as of a protein or of a nucleic acid, 
results in turn in a therapeutic benefit to the patient. In its basic sense, rational drug 
discovery involves the design of molecules that, showing a highly complementary 
chemistry to a specific target, can interact with it, starting a cascade of biochemical 
responses. In addition to organic small molecules new classes of drugs become 
everyday increasingly important as, for example, biopharmaceuticals and especially 
therapeutic antibodies. In order to test and validate these protein-based therapeutics, 
different techniques for improving the affinity, selectivity, and stability of them have 
also been developed [2]. 
In the drug design process, prediction of binding affinity is nowadays the most 
improved task and, at the same time, the most reliable. However, there are many 
other properties, such as bioavailability, metabolic half-life, and side effects that 
must be optimized prior to get a safe and efficacious drug. These pharmacokinetic 
parameters are yet difficult to predict through rational design techniques. 
Nevertheless, today, more attention has been focused on selecting candidate 
molecules presenting physicochemical properties that can lead to fewer 
complications during development and hence can help in the pathway from lead 
compound to marketed drug [3]. Furthermore, in silico methods, used prior to in 
vitro experiments, have shown a huge benefit in predicting possible ADME 
(Absorption, Distribution, Metabolism, and Excretion) properties for the potential 
candidates as well as their toxicological profiles [4]. In contrast to traditional 
methods of drug discovery based on testing candidate drugs through in vitro and in 
vivo assays, and connecting the retrieved effects to treatments, rational drug design is 
based on an initial hypothesis that a desired effect is due to the modulation of a 
precise biological target, specifically tuned by a structurally complementary 
molecule. The first issue of rational drug design is the knowledge of the real 
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involvement of the target in the studied biochemical disease pathway. This can be 
sometimes confirmed by the association between target mutations and disease states 
[5]. The second is the druggability of the chosen target. This relies on the target 
capability of binding to a small molecule for the modulation of its activity [6]. In a 
rational drug discovery protocol, the research of small molecules potentially capable 
to bind to a specific target begins with a screening of libraries containing probable 
drug candidates. This process can be assessed as “wet screening” or may be done 
through the computational means searching for drug and lead-likeness of compounds 
[7]. Several methods are available to estimate drug-likeness such as Lipinski's Rule 
of Five and a range of scoring methods such as lipophilic efficiency [8]. 
The optimisation process of a drug design protocol is characterised by a huge 
number of properties that must be simultaneously tuned. For this reason, it is of 
common use to adopt some multi-object optimization techniques [9]. Finally, despite 
all the efforts made in the last years to optimise drug discovery protocols, a 
successful drug design campaign seems to be mostly reliant on serendipity and 
bounded rationality [10]. 
 
In the last years, the application of computational techniques in drug discovery and 
development process has gained in popularity, implementation, and appreciation. 
Different terms have been applied to this area, the most common used are computer-
aided drug design (CADD), molecular modelling and in silico drug design. The 
success behind CADD application is due to its capability of increasing the hit rate of 
novel drug compounds when compared to the classical HTS approach. Compared to 
the latter, in silico methods allow the use of combinatorial chemistry and a much 
more targeted search, thanks to publicly available databases growth. The main scope 
of molecular modelling is to explain the molecular basis of therapeutic activity of 
some molecules and predict possible derivatives that would improve activity [11, 
12]. In a drug discovery campaign, computational techniques are usually used for 
three major purposes: 
 (1) Filter large compound libraries into smaller sets of predicted active compounds 
that can be tested experimentally leveraging chemical and biological information 
about ligands and/or targets to identify and optimize new drugs; 
 
 (2) Guide the optimization of lead compound, whether to increase its affinity or 
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optimize drug metabolism and pharmacokinetics properties such as absorption, 
distribution, metabolism, excretion, and the potential for toxicity (ADMET); 
(3) Help in the rational design of novel compounds, either by modifying starting 
molecules or by tying together fragments into novel chemotypes.  
Fast expansion in this area has been made possible thanks to advances in 
computational software and hardware, and increasing database of publicly available 
ligand molecules and target protein structures. One of the most important advantages 
in the use of in silico methods is the reduction of chemical space size and, thereby, 
the possibility to focus on more promising candidates for lead discovery and 
optimization. The main goal of virtual screening is therefore to eliminate compounds 
with undesirable properties and enrich the set of molecules with desirable properties. 
In another words, in silico modelling is used to significantly minimize time and 
resource requirements of chemical synthesis and biological testing. As shown in Fig. 
1.1, in silico methods become nowadays more and more important as a first step of 
the entire workflow for the drug discovery process, avoiding possible false positive 
or false negative results in the search of possible hits to develop. In the last years, in 
fact, there has been a rapid growth of virtual screening usage, as confirmed by the 
increase in the number of citations matching keywords “virtual screening”. By using 
the SCOPUS database [13], it is possible to check that the articles explicitly 
reporting the keyword “virtual screening” steeply increase about the year 2000 
reaching a number of articles 20 times higher in 2015. 
! 4!
 
Fig.1.1 Virtual screening workflow adopted prior to in vitro assays 
!
D.V. Green of GlaxoSmithKline in a review published in 2003 concluded with: “The 
future is bright. The future is virtual” [14]. Already in 2003, it was estimated that 
computer modelling and simulations would account for ~ 10% of pharmaceutical 
R&D expenditures and that they will have rose to 20% by 2016 [15]. In these days, 
PriceWaterhouseCoopers has published “Pharma2020”, the latest market research 
about the state of the art and the future of computational chemistry within the 
pharmaceutical companies [16]. In Fig. 1.2, the comparison between the state of the 
art and future predictions is reported. 
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Fig.1.2 comparison between state of the art and future predictions in CADD usage in pharma 
industries 
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Referred to CADD there are two major types of drug design. The first is referred to 
as ligand-based approach [17], and the second, structure-based [18] Fig. 1.3. 
 
Fig.1.3 Ligand-based and Structure-based approaches in drug discovery 
 
Ligand-based drug design is usually adopted when there is no 3D structural 
knowledge of the target studied. The use of molecules known to be active on the 
biological target of interest is the starting point used for such an approach. This kind 
of design strategy is also called indirect drug design because, starting from known 
active compounds on a specific protein, it tries to find the essential chemical features 
useful for interacting with that target. Once all the structural information has been 
collected it is in fact possible to search for chemical similarity between known and 
new molecules. One of the most applied ligand-based approaches is based on the 
indirect building of a pseudo receptor derived from a pharmacophore model that 
defines the minimum necessary structural characteristics a molecule must possess in 
order to bind to the target. In other words, a model of the biological target binding 
pocket may be built based on the knowledge of what binds to it, and this model in 
turn may be used to design new molecular entities that interact with the target [19–
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21]. A pharmacophore model can be considered as an abstraction of molecular 
features necessary for the molecular recognition between a ligand and a biologic 
macromolecule. The IUPAC defined it as “an ensemble of steric and electronic 
features that is necessary to ensure the optimal supramolecular interactions with a 
specific biological target and to trigger (or block) its biological response” [22].  
The pharmacophore features include hydrophobic centroids, positive or negative 
ionisable sites, hydrogen bond acceptors or donors and aromatic rings (Fig.1.4). 
These pharmacophore features may be located on the ligand or may be project points 
presumed to be located in the receptor [23]. 
 
 
Fig.1.4 Pharmacophore model generated with Ligandscout software. In yellow 
hydrophobic features are represented, hydrogen-bond acceptors are signed in red 
and hydrogen-bond donors in green. Blue rings stands for aromatic features 
 
Another common ligand-based method relies on cheminformatics. In this case, 
ligand structural information is converted into molecular descriptors, and, through 
statistical analysis, one can predict possible target for a new molecule. This kind of 
prediction is based on the structural similarity between the new molecule and a 
known set of compounds. Such an approach has been developed and applied to the 
search of new potential drugs [24, 25]. Ligand-based drug design can be also 
exploited to search for a quantitative structure-activity relationship (QSAR). In this 
approach, one can determine the statistical correlation between calculated properties 
of molecules, expressed as molecular descriptors, and their experimental biological 
activity. Once found the most robust model, the information can be exploited to 
predict the activity of new analogues [26, 27]. A QSAR model has the form of: 
 
  Eq.1 
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In the last years, a more complete approach has been developed: 3D QSAR. This 
term refers to the application of force field calculations based on three-dimensional 
structure of molecules. It exploits the calculation of non-covalent empirical 
potentials between atom couples, such as the Lennard-Jones potential, rather than 
using experimental constants to define the interatomic interactions. Some of the 
parameters analysed are the steric fields (shape of the molecule), the hydrophobic 
regions (water-soluble surfaces), and the electrostatic fields [28–30]. 
 
Structure-based drug design exploits the knowledge of the three dimensional 
structure of the biological target, obtained through methods such as X-ray 
crystallography or NMR spectroscopy [31, 32]. The lack of target 3D structure can 
be overtaken by means of a homology model of the target, using the experimental 
structures of similar proteins. In this case, the studied protein will be folded 
according to the amino acid sequence homology with other proteins having known 
folding structures [33, 34]. In case of low homology levels, it is possible to assess 
folding prediction through the use of protein threading. In this technique, also known 
as fold recognition, each amino acid in the target sequence is assigned to a position 
in a template structure, and an evaluation of how well the target fits the template is 
done. After the best-fit template is selected, the structural model of the sequence is 
built [35, 36]. Starting from the knowledge of the biological target structure, 
candidate drugs can be optimally designed by medicinal chemists, predicting their 
binding affinity and selectivity. The two main structure based techniques are the 3D 
pharmacophore modelling [21, 37, 38] and molecular docking [39, 40].  
Pharmacophore modelling is more and more preferred to docking for several reasons. 
First of all, it is more universal. In fact, pharmacophores represent chemical 
functions, applicable not only to a specific bounded molecule, but also to unknown 
ones. Secondly, it is very efficient because the computational resources needed for 
the pharmacophore modelling are really poor. For this reason, it is very suitable for 
large libraries virtual screening. In the end, it also allows researchers to tune it on the 
fly adding and removing features or adjusting their tolerance in order to optimise 
both the sensitivity and selectivity of the screening.  
Molecular docking is usually applied to deeply evaluate the interaction between a 
small molecule and a protein at the atomic level. This helps to study the behaviour of 
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small molecules in the binding site of target proteins and to deepen biochemical 
paths. The docking protocol consists of two main parts: firstly, the prediction of the 
ligand position, conformation and orientation within the binding site (usually 
referred to as pose) then, on a determined pose, the evaluation of the binding affinity. 
These two steps rely on what is defined as searching algorithm (for the pose 
research) and scoring function, for the binding affinity calculations [39, 41]. 
Different types of molecular docking have been developed in the last years. The two 
main approaches exploit ligand flexibility or receptor and ligand flexibility 
respectively. In the former, ligand conformations may be generated prior to docking 
or within the receptor binding cavity [42]. To select proper energetically 
conformations of ligands, knowledge-based [43] or force field-based methods  are 
used [44].  
The above mentioned in silico approaches used in drug design can be roughly further 
classified based on the purpose of their application [45]. One of the most used 
applications of CADD is the virtual screening. It consists in the search of new 
ligands as potential drugs for a specific target by searching large databases of 3D 
structures of small molecules that can well fit into the binding pocket of a protein or 
on a pharmacophore model. A second strategy is the de novo design of ligands. In 
this case, molecules are designed starting from the essential interaction pattern within 
the binding pocket by assembling molecular fragments that can satisfy those 
interactions. The strength of such an approach is that molecules created are not 
present in any database, but are new entities [46]. The last approach consists in the 
optimisation of already existing molecules to maximise the efficacy or to minimise 
side effects while maintaining the essential features to interact with the chosen target 
[47]. 
In the last years a new way of using CADD has been more and more adopted. It is 
based on the integration between screening techniques with simulation ones as, for 
example, Molecular Dynamics (MD). 
MD in drug design has demonstrated to give a huge impact in the improvement of 
drug design strategies. The knowledge of molecular motions can be fundamental for 
understanding compatibility between two different molecules. Thanks to the modern 
techniques, the initial idea of a frozen receptor that can accommodate a small 
molecule without mutating its conformation –also known as “Lock-and key” model 
[48] - has been largely substituted by a modern idea of dynamic receptor that 
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undergoes some conformational changes based on the ligand to bind [49, 50]. In 
Figure 1.5 the general process of molecular dynamics calculations is reported. 
 
Fig.1.5 Simplified Scheme of molecular dynamics calculations 
 
The first step of MD is the availability of a 3D target structure. This can be obtained 
throughout X-ray crystallography, Nuclear Magnetic Resonance (NMR), or by 
homology-modelling. The 3D coordinates of the receptor structure will be used as 
starting point for the integration of the equation of motion. For this calculations, 
Energy, expressed as forces between atoms, is calculated exploiting Force Field (FF) 
parameters according to the formulas reported in Figure 1.6 [51]. The FF contains all 
the information useful for the calculation of the total energy of the molecules, 
including bonded and non-bonded terms relatives to atoms within the simulation. 
In FF parameters, the bonded part of measurement contains chemical bonds 
stretching and atomic angles variations modelled as simple virtual springs. Dihedral 
angles are instead represented by sinusoidal functions that approximate the energy 
differences between eclipsed and staggered conformations. The non-bonded terms 
are represented by van der Waals interactions, for the neutral species, Lennard-Jones 
6-12 potential, and using Coulomb’s law for the charged interactions [52].  
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Fig.1.6 Example of empirical Force Field parameters 
 
Even though current force fields present some weaknesses because of several 
approximations and simplifications, MD simulations play today a very important role 
in drug discovery because they are the only way to study receptor motions. Just a 
single protein conformation, for example, tells little about protein dynamics. The 
static models can be valuable to study the structure of a protein, but drug binding or 
molecular recognition in general are dynamic processes otherwise not 
comprehensible if not through the use of MD. The molecular recognition process 
involves in fact different possible arrangements of both ligand and protein and not 
their unique and static conformation. 
Following the receptor theory, ligands can bind and stabilize only a subset of the 
different conformations of a receptor and this can cause an induced shift of all the 
receptor conformations towards the most appropriate to bind the ligands [49]. 
Moreover, once bound to the protein, the ligand can induce some rearrangements in 
the binding pocket that are not reproducible in its absence [53]. In the last few years, 
several approaches have been adopted to simulate the flexibility and dynamicity of 
the receptors to adopt in virtual screening campaigns. For example, recently, Lexa et 
al. published a review where it is possible to study all the different approaches 
adopted in order to take into account protein flexibility for molecular docking [54]. 
Herein, some of the mentioned methods are presented. One of the most common 
approaches is the so called “soft docking”. This technique exploits the attenuation of 
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the Lennard–Jones repulsion term between the receptor and the ligand allowing some 
minimal backbone movement and side-chain flexibility. Movements are then 
followed by a rigid-body protein relaxation protocol [55].  In the relaxation methods, 
the docked complex is taken as a starting point for focusing on protein flexibility by 
modelling induced-fit effects. The main limitation of this approach is that the 
dynamic simulation can be only assessed on an all-atom structure: it cannot be 
performed if the protein is not explicitly represented (e.g. docking grid). Monte Carlo 
(MC) or MD simulations are actually the most adopted techniques to perform 
complex relaxation and interactions study. Such a kind of refinement is usually 
performed after the docking process is finished and the best pose for docking is 
chosen and it allows other investigations such as solvent effects, examination of the 
kinetic stability, and prediction of ΔGbind [56, 57]. The last two methods present the 
limitation that there is not a real view to the conformational modification of the 
target during the binding process with the ligand. For these reasons other new 
algorithms have been proposed, for example the induced fit docking method. In the 
latter, the docking simulation is run considering ligand and protein side chains as 
flexible to explore new conformational space. The main limitation of such an 
approach is that its computational requirements are a limitation feature, especially on 
large-scale virtual screening studies. Furthermore, the only conformational space of 
the protein is relative to side chains rotamers, it is in fact based on the use of side 
chain conformation libraries [58, 59]. Most published methods for flexible protein–
ligand docking are based on a limited number of receptors and are usually applied to 
small molecule libraries, that make the evaluation of the methods difficult. The use 
of a large test set is in fact vital in the performance assessment of a new screening 
method especially when one wants to measure performance across a range of 
different targets. Moreover, the use of a dynamical approach to docking is more 
resource and time-intensive than semi-flexible docking.  
The use of multiple receptor conformations for docking however may sometimes 
decrease the selectivity of the screening process increasing, for example, the false 
positive rate. The use of multiple conformations may also lead to the creation of a 
ligand optimal for an average receptor structure that is not experimentally accessible, 
a so-called ‘paradoxical inhibitor’. To avoid this kind of risks it is possible to take 
into consideration only receptor conformations that are present in low-energy 
landscape of the protein. This issue has driven many researchers to focus on the 
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choice of the optimal method for the selection of the possible receptor conformation 
to adopt in the screening process. 
The dynamic approach has also been adopted in pharmacophore based virtual 
screening. In these cases, structure-based pharmacophore features are generated 
starting from protein-ligand complexes taken from molecular dynamics. Recently, a 
dynamic pharmacophore approach has been proposed by Choudury et al. In their 
work, some snapshots are extracted from MD and structure-based pharmacophore 
models are generated within the protein-ligand complexes chosen. The built models 
are then compared with the docking approach using known active and inactive 
compounds [60].  
Another way to study dynamic pharmacophore, starts from MD to cluster trajectory 
frames based on the root mean square deviation (RMSD) of the protein-ligand 
system or the most populated conformations of the receptor [61, 62]. The RMSD for 
frame x is reported in Equation 2. The procedure is repeated for every frame in the 
simulation trajectory. 
 
  Eq.2 
 
where N refers to the number of atoms in the analysed selection; 
tref is the reference time, (typically the first frame is adopted as the reference 
and it refers to time t=0);  
r' is the position of the selected atoms in frame x after it has been superimposed 
on the reference frame, where frame x is recorded at time tx.  
 
One of the limitations of these approach is represented by the dismissing of the 
dynamic information from the MD simulations and the consideration of only some 
coordinates chosen by the operator. Such a method is in fact strongly biased by the 
ability of the MD simulation to represent the configurational space and the operator 
capability to select the most representative frames out of the whole simulation [63, 
64]. Moreover, the ligand binding process could be related to a unique receptor 
conformation, maybe not representative in the dynamic trajectory and this could be 
missed in the clustering approach. In this case the use of dynamic pharmacophore 
represent a real thread for the virtual screening campaign [65, 66]. 
The methods described above, developed for integrating protein flexibility in 
docking and pharmacophore modelling present several flaws and the output 
generated could be of ambiguous correctness. Overall, the main, problematic step 
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always seems to be the correct choice of protein conformation to adopt to generate 
docking grid or pharmacophore models.  
For molecular docking, one should run a number of virtual screening experiments 
equal to the number of obtained coordinate sets. Unfortunately, the choice of 
significant structures is no obvious because it is not possible to detect a priori which 
coordinate set will give good results in virtual screening. From a virtual screening 
point of view, in fact, every protein conformation that results in a differently ranked 
molecule list contains potentially important information. 
For the pharmacophore approach, the models generated from the MD trajectory (one 
pharmacophore model for each coordinate set) are equal to the number of screening 
runs and also in this case every model carrying out new information could be crucial 
in the realisation of a screening campaign. Comparing the two methods, dynamic 
structure-based pharmacophore models present less variability compared to the 
dynamic docking approach based on the coordinate of the amino acid side chains. 
Pharmacophore feature space is very limited compared to configuration space of the 
protein side chains coordinates. The geometry tolerance of the pharmacophore 
features allows to find the same models for slightly different protein configurations.  
A possible evident solution for reducing bias in the dynamic approach to virtual 
screening could be the development of a protocol capable to really explore all the 
coordinates generated during the MD simulation without having to choose some 
structures or conformations. Obviously such an approach results to be very time and 
resources consuming and it is strongly related to the number of atoms to simulate and 
to the libraries to screen.  
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2! AIMS OF THE WORK AND OUTLOOKS 
!
The aim of my PhD project was the development, optimisation, and implementation 
of new in silico virtual screening protocols. 
Specifically, this thesis manuscript is divided into three main parts, presenting some 
of the papers published during my doctoral work. 
The first one, here named CHEMOMETRIC PROTOCOLS IN DRUG 
DISCOVERY, is about the optimisation and application of an in house developed 
chemometric protocol. This part has been entirely developed at the University of 
Palermo - STEBICEF Department - under the guide of my supervisors. During the 
development of this part I have personally worked on the tuning and optimisation of 
the algorithm and on the docking campaigns to obtain molecule conformaitons. 
The second part, THE APPLICATION OF MOLECULAR DYNAMICS TO 
VIRTUAL SCREENING, presents a new approach to virtual screening, in 
particular the attention is focused on different approaches to the application of 
protein flexibility and dynamics to virtual screening.  
This part, has been carried out in cooperation with the University of Vienna - 
Department of Pharmaceutical Chemistry. For these works I have worked in the 
development of the general workflow, to a lesser extent to the programming (coding) 
part of the applications used and I mainly focused on the realisation of the screening 
campaigns and results interpretation.  
The third and last part, COMPUTATIONAL CHEMISTRY IN POLY-
PHARMACOLOGY AND DRUG REPURPOSING, concerns the study of the in 
silico methods applied to two main topics of the drug discovery process, such as the 
drug repurposing and the polypharmacology. In this part I will briefly describe what 
published in two reviews dealing to the above mentioned topics. 
In conclusion during this doctoral project, I have demonstrated how the use of in 
silico tools can be useful in the drug discovery process. The Chemometric protocols 
developed and optimised represent in fact a helpful strategy to use for target fishing. 
Whereas, the application of molecular dynamics to virtual screening, especially for 
pharmacophore modelling, is a new way to deepen crucial features to be adopted in 
the search of new putative active compounds. 
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3 CHEMOMETRICS AND DRUG DESIGN  
 
Some of the in silico methods such as molecular docking and pharmacophore 
modelling could be considered as the modern virtual application of the elderly lock-
and-key model based on the structural complementarity between a ligand molecule 
and a receptor [48, 67, 68].  
In the recent years, these methods have demonstrated to give an important boost to 
the pharmaceutical research. On one hand there has been an increase of the 
computational approaches reliability. On the other hand, however, the putative leads 
discovered through the computational methods, once synthesized and tested in vitro 
can sometimes disappoint the researchers’ expectations. Such a problem causes a 
waste of a huge amount of time and resources. Moreover, some of the discarded 
compounds can be instead potentially good candidates to develop. Such a kind of 
issue is always referred as a false positive and false negative ratio capability of a 
virtual screening technique. Another interesting aspect is that compounds that 
sometimes are discarded for a target, can be interesting on others, as suggested in 
several works [69, 70]. For instance, two main aspects known as 
“polypharmacology” and “drug repurposing”, are known to have shifted researchers’ 
efforts to constantly try to characterize drug-biological target associations [71, 72].  
The structural knowledge of targets and ligands has allowed to use chemical and 
sequence similarities among molecules and receptors to identify putative drugs to be 
addressed towards different targets in [73, 74]. For this reason, in the first stage of a 
drug discovery campaign could be useful to test early candidates towards a panel of 
different biological targets [75]. The possible correlation between ligand and target 
structures is a well-known issue, but unfortunately today it is still not possible to 
unambiguously interpret it.  
In computational chemistry, the molecular structure can be identified and categorized 
by molecular descriptors. Molecular descriptors have been successfully adopted by 
several disciplines, such as chemistry, pharmaceutical sciences, environmental 
protection policy, and health researches, as well as in quality control. These 
parameters can be considered as the translation of a chemical property (i.e. chemical 
structure) into numbers. This kind of conversion, allows treating chemical properties 
from a mathematical point of view, expanding the exploration panorama that can be 
applied to molecules. As defined by Roberto Todeschini [76, 77]: 
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"The molecular descriptor is the final result of a logic and mathematical 
procedure which transforms chemical information encoded within a symbolic 
representation of a molecule into a useful number or the result of some 
standardized experiment." 
 
Following this definition, molecular descriptors can be categorized into two main 
groups: theoretical molecular descriptors, directly connected to the symbolic 
representation of the molecule, and physico-chemical properties or experimental 
measurements, such as logP or molar refractivity. 
In molecular modelling, theoretical molecular descriptors are usually adopted. This 
group can be further considered as a collection of smaller groups:  
•!  0D-descriptors (i.e. constitutional descriptors, count descriptors); 
•!  1D-descriptors (i.e. list of structural fragments, fingerprints); 
•!  2D-descriptors (i.e. graph invariants); 
•!  3D-descriptors (such as, for example, 3D-MoRSE descriptors, WHIM 
descriptors, GETAWAY descriptors, quantum-chemical descriptors, size, 
steric, surface and volume descriptors); 
•!  4D-descriptors (such as those derived from GRID or CoMFA methods, 
Volsurf). 
The above classification is taken from the book “The handbook of molecular 
descriptors” by Roberto Todeschini [77].  
The use of a single molecular descriptor is not enough to predict a biological target 
for a molecule. However, the use of a carefully selected set of molecular descriptors 
can be a very powerful translator that can reveal important information about 
necessary structural features of a molecule to interact with a specific receptor. For 
example, topological descriptors based on a multiple bioactive reference structures 
have been employed in similarity-based virtual screening, showing to be potentially 
more effective than fingerprints, scaffold-hopping or ligand topological 
pharmacophores [78, 79]. 
Recently, the use of molecular similarity approach, has been more and more adopted 
for the discovery of some potential lead compounds [80]. Nonetheless, it is important 
to point out that a chemical similarity between two molecules, expressed as similar 
molecular descriptors’ chemical space, is not always synonym of same biological 
activity [81, 82]. 
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In the last years, the research group I worked with for my PhD has developed an 
approach based on the use of the molecular descriptors as the mean through which 
building biological lock models for different targets in order to identify new putative 
drug molecules. This indirect approach starts with the calculation of molecular 
descriptors for known inhibitors of a selected target. Based on the molecular 
descriptors values, the idea is to build a target profile, here called lock model, which 
is created on the structural features of its specific binders. The research of new 
candidates is based on the possibility of finding new molecules responding to the 
structural requisites for the target profile previously created [24]. 
All the chemical structures have been collected from the BindingDB, a Public 
database including chemical structures classified by biological activity [83]. 
The first key step of this in house method, called Virtual Lock-and-Key Approach 
(VLKA), was the random choice of 47 biological targets, form now indicated as Tn 
presenting known inhibitors with measured biological activity available in the 
BindingDB. 
Starting from these structures, known inhibitors were chosen from BindingDB and 
CODESSA PRO software [84] was used in order to calculate a set of molecular 
descriptors. This software is able to calculate about 1000 molecular descriptors, from 
0D to 3D. As mentioned before, the aim of the protocol is to build a lock model for 
each biological target (Tn) starting from a target profile traced by molecular 
descriptors value of its known inhibitors. In order to choose a compound selection 
for the lock model constitution, a biological data cut-off was adopted (Ki, IC50, 
EC50) [24]. For the creation of the protocol, 173 molecular descriptors were chosen 
in order to have not blanks for all the selected compounds constituting the lock set. 
For the calculation of 3D-molecular descriptors, global minimum conformations 
from in vacuo minimisation were selected. Mean (m) and standard deviation (s) of 
the molecular descriptors values (Xi,j) for each biological target (Tn) were calculated 
(Fig. 3.1A). The hypothesis behind the protocol is that the value of each molecular 
descriptor of a suitable inhibitor should be close to the same molecular descriptor 
mean (m) calculated for all the inhibitors of the same biological target. Starting from 
that, every molecular descriptor value [Xi,j(Tn)] of the compounds, included in the 
Lock set, was converted into a numerical coefficient in relation the closeness to m 
(Fig. 3.1B), as reported in Eq. (3.1): 
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if Xi,j(Tn) > µ ± σ, ! α = 0; 
(eq.3.1) if (µ-½σ) < Xi,j(Tn)< (µ+½σ), ! α = 1;  
if –σ < Xi,j(Tn) <-½σ, ! α = 0.5; 
if +½σ < Xi,j(Tn) <+σ, ! α = 0.5. 
 
where: X represents the molecular descriptor value; 
i is related to the structure; 
j is related to the molecular descriptor; 
Tn represents the biological target. 
 
Basically, each biological target needs specific chemical-physical properties to be 
activated, so, it is wise to assume that some molecular descriptors could express 
better than the others the key structural requirements for the specific biological 
target. Starting from this consideration, the molecular descriptors values were 
weighed for each Tn on the basis of the α coefficients determined for the lock set, by 
considering the sum of the α value for each descriptor (Dj) for all compounds, 
belonging to the specific biological target (Fig. 3.1C). The following step was to 
normalize these values by defining the !Dj coefficients (Fig. 3.1D) as reported in 
Eq. (3.2).  
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Fig. 3.1 Virtual lock-and-key approach flow chart. A: Calculation of Mean (m) and 
standard deviation (s) of the molecular descriptors values (Xi,j) for each biological 
target (Tn); B: Conversion of each molecular descriptor value [Xi,j(Tn)] in a 
coefficient; C: Molecular descriptors weighing by a coefficient for each biological 
target (Tn); D: Normalization step by defining the uDj coefficients; E: Partial scores 
4 calculation; F: Total score V calculation  
 
     (eq. 3.2) 
where: i, j, and Tn are defined in Eq. (3.1);  
 
 
represents the higher α sum of all 
molecular descriptors belonging to 
specific biological target. 
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The αi,j(Tn) and ωDj coefficients were used to calculate the affinity of all the 7352 
compounds under investigation for each biological target. Thus according to Eq. 
(3.4) the partial score φ was calculated, and the total score Φ was defined as sum of 
φ Eq. (3.3) (Fig. 3.1 E-F). 
 
 
(eq. 3.3) 
 
(eq. 3.4) 
where: "i,j represents the partial score; 
# represents the total score; 
i, j, and Tn are defined in Eq. (3.1) 
 
All the calculated scores, for all the structures for each biological target were 
converted in rankings. 
 
At the end, the Φ scores rank all the 7352 database compounds with respect to the 47 
biological target. Inhibitors related to each biological target should occupy the higher 
rankings. To verify this hypothesis the enrichment score (E%), considered as the 
percentage of correct classification, was calculated according to eq. (3.5): 
 
 
  (eq. 3.5) 
where: W represents hypothetical lowest rankings; 
B represents hypothetical highest rankings; 
P represents the obtained rankings. 
 
Two different E% scores: E%1 related to the “lock set”, and E%2 for the “total set” 
of a biological target were calculated. The E%1 reached an average value of 80.4% 
and for many targets values up to 95%, and the E%2 reached an average value of 
79.0% (Fig. 3.2). 
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Fig.3.2 E% for the lock and total set!
 
As previously mentioned, the core of VLKA protocol consists in setting-up a “lock 
model” for a biological target, starting from the respectively known inhibitors. In this 
scenario, molecular descriptors could be considered as pins of a lock (receptor 
binding pocket) to be released by a key (molecule) (Fig. 3.3a). Considering this 
assumption, a new molecule could be considered an inhibitor of a biological target if 
the values of its molecular descriptors fall in the calculated range values for the set of 
known inhibitors for the same target. 
Briefly, for each structure, the range of molecular descriptors constituting a “lock 
pin” were defined considering the mean value of them (D mean) and the standard 
deviation (s) as tolerance (Fig. 3.3b). When the molecular descriptors values of a 
molecule fall into these defined ranges the lock can be released and the structure can 
be considered as a potential inhibitor (Fig. 3.3c). 
To be released, a real lock needs that all pins must fit the lock structure whereas, in 
this protocol, the higher is the number of fit pins, the higher will be the affinity to the 
considered biological target. 
In the VLKA, the biological target lock pins are represented by a sequence of 173 
molecular descriptors. 
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Fig. 3.3 From the lock to biological target. a) How a real lock works; b) The range 
of “lock pin” molecular descriptors values (mean m ` s) can be considered the “pin 
tolerance”; c) When all the molecular descriptors values fall into the “pin 
tolerances” the biological target “releases”.  
 
The affinity score of a molecule against a specific target is then evaluated as the 
number of the molecular descriptors “fitted” (Fig. 3.3). 
Moreover, as mentioned before, not all the molecular descriptors have the same 
weight in the lock constitution: some of them are really representative for the lock 
while some of them can be omitted. So it was necessary to prioritize some 
descriptors among others. Using this approach, it was possible to rank molecules of 
the training set based on their affinity against the protein set. What was expected 
from these assumptions was that inhibitors of a specific biological target should be 
retrieved in the higher ranking positions for that target. 
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3.1 Conf-VLKA: A structure-based revisitation of the 
Virtual Lock-and-Key Approach
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3.1.1 Introduction 
 
Starting from the in house application VLKA, in the attempt to deepen the ligand 
conformation influence on the protocol, we decided to test the same previous 
algorithm of scoring and ranking starting from the docked conformation of ligands. 
Docking calculation was used for two different purposes: to retrieve docking scores, 
first (in order to test the algorithm for target assignation and possible off target 
application), then to provide the docked pose of ligands into the relative targets to be 
used in the VLKA method. The docked ligand poses were in fact used to re-calculate 
the 142 3D-descriptors (Conf-VLKA), out of the total 173 descriptors originally used 
in the VLKA. In fact, the remaining 31 descriptors out of the initial 173 set were 1D 
and 2D, and they did not need to be re-calculated because not influenced by ligands 
conformation. The original VLKA results, based on molecular descriptors obtained 
with in vacuo optimized structures [24], were then compared to the new approach in 
the attempt to evaluate the likely influence of 3D ligand conformation on the 
protocol prediction capability. The comparison between the two methods was also 
made, by analysing docking results in scoring and ranking molecules, for the 
different targets [85].  
 
3.1.2 Material and Methods  
Target choice 
Being the most important issue of the approach the comparison of the new protocol 
with the previous one, we decided to maintain the same targets and ligands of the 
original method [24]. 
VLKA algorithm: scoring and ranking 
For the algorithm details please refer to the previous paragraph VIRTUAL LOCK 
AND KEY APPLICATION [24]. 
Ligand Structure similarity evaluation  
In order to check the structural diversity of ligands for each target set, preventing the 
enrichment of redundant molecular analogues, we set up a topological evaluation of 
the whole database. For each target, ligand structures were submitted to calculation 
of radial fingerprint [86], molprint2D fingerprint [87] and MACCS keys [88] and 
then analysed in terms of Tanimoto distance [89] using similarity matrix on 
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CANVAS [90, 91]. The Tanimoto similarity cut-off value usually chosen as index of 
similarity is above 0.75 [92]. 
3D biological structures selection and optimization 
To carry out this comparative approach, the 3D structures of the biological targets 
included in the VLKA have been downloaded from the RCSB Protein Databank 
(PDB) [93], complexed with co-crystalized ligands. The selected structures were 
submitted to the optimization and refinement process using Protein Preparation 
Wizard utility of Maestro Schrödinger suite. During this process bond orders were 
assigned, the missing hydrogens were added, the disulfide bonds were eventually 
assigned, the water molecules were deleted, the protonation of aminoacids were 
determined. At the end, the hydrogen bonds of the proteins were optimized, and 
restrained minimization was carried out on heavy atoms converging to RMSD equal 
to 0.30 Å, and on the hydrogen atoms. 
Docking and descriptors calculation 
The ligands co-crystalized within PDB structures were extracted and docked using 
Glide XP high performance docking procedure [94–96], as a test for pose prediction 
quality of the searching docking algorithm. The 7352 compounds of the VLKA were 
submitted to the docking and scoring procedure versus the own target, and then 
versus the entire biological targets dataset. The best ligand pose for each compound 
was selected according to the XP Glide Score. Once docked, 3D molecular 
descriptors for the best pose structures were re-calculated as in the original work 
[24]. 
 
3.1.3 Results and Discussion 
 
The aim of this work was to explore the VLKA protocol capability using docked 
conformation of ligands. The original approach was based on molecular features of 
known inhibitors expressed as 1D, 2D, and 3D descriptors calculated on in vacuo 
conformation of molecules. The new method was based on the 3D descriptors 
calculation on the best docked conformations of each compound. This last approach 
(Conf-VLKA), in our opinion, could give a new interesting point of view due to the 
fact the original descriptor matrix consisted of only 31 1D/2D descriptors over 173, 
the total descriptors used [24]. So it is plausible to observe a variation in most of the 
values due to the change of 3D conformation of molecules. Consequently, the 
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“locks” and the pin tolerance could result different from the original VLKA. To set 
up the study, biological targets were taken from RCSB Protein Data Bank. 43 out of 
47 biological targets were retrieved into the PDB because of a lack for some 3D 
structures such as CAMK2 (Calmoduline Kinase 2), CB2 (Cannabinoid Receptor 2), 
Ghrelin Receptor (GHSR), and Diacylglycerol acyltransferase (DGAT-1). Even 
though it is common practice to re-build protein structures by means of homology 
modelling, when these ones are not available in databases, this procedure, starting 
from the primary sequence, allows obtaining calculated structures and hence less 
reliable structures respect to experimental ones. So, finally we decided to discard 
targets for which 3D-structures were unavailable. For many targets, multiple 
structures were retrieved, and for some targets (CA-4, CDK4, CT), no bound ligand 
was available. All the 3D biological structures, taken into account, are reported in 
Table 3.1. 
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Table 3.1. Target PDB ID and relative crystalised ligands codes 
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Table 3.1. cont.  
 
 
According to the Glide docking procedure, target grids were calculated on the 3D 
coordinates of the crystallised ligand within the PDB crystal. For those targets not 
bearing any ligand, we decided to exploit the PDBsum database information to 
calculate target grids [36], on the residues identified to be part of the binding pocket. 
Cognate docking was applied to the PDB dataset to test the docking searching 
algorithm capability. The root mean square deviation (RMSD) between the re-
docked pose of the ligand and the original co-crystalized one was the accuracy 
parameter chosen. Generally, the lowest is the RMSD the most accurate is the 
docking algorithm, this also allowing us to choose the more suitable target structure 
(Table 3.2).  
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For systems presenting more than one PDB available, the one presenting the lowest 
RMSD value was chosen. The cut-off value for choosing a system was set as < 2.0 
Å. For a few systems we had to choose the lowest value that was anyway quite 
higher than 2.0 Å (Table 3.3). 
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Table 3.2. RMSD values for targets with multiple 3D structures 
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Table 3.3. 3D PDB structures selected 
 
The next step was the application of the docking on the 7352 VLKA compounds. For 
each target, docking calculations were performed on specific target compounds (lock 
set and total set), and on the rest of the entire VLKA dataset. For three targets 
(Asparaginyl Endopeptidase, AE; Aldosterone Syntase, CYP11B2, Delta Opioid 
Receptor, DOR), no docked pose was generated for the majority of the compounds, 
so we decided to exclude them from the analysis because not significant. The best 
pose for each molecule was chosen according the Glide Score and visual inspection 
in order to avoid atomic clashes. The docked conformation of molecules was then 
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submitted to the VLKA algorithm. As previously explained, in the VLKA, the 
structural affinity of a compound towards a specific target is expressed by a score 
(Φ), calculated on the weighted average values of molecular descriptors. Based on 
this parameter each compound is ranked versus each receptor creating the E% score 
for every target analysed; the highest is the score, the highest is the probability that 
the ligand is correctly assigned to its target. At this step of our study, we replaced the 
Φ scores with the docking scores, and recalculated the E% scores. The application of 
docking protocol gave us results for 40 out of 47 targets included in the original 
VLKA. The simple use of docking algorithm for target assignment of molecules 
pointed out that E%, both in case of lock set (E%1) and test set (E%2), are lower 
than the E% scores of the original VLKA, with a mean value of 60.0%. Just for few 
targets, the E% scores exceed the 80.0% (Figure 3.4). These results reflect that the 
use of docking scores did not revealed suitable for this kind of approach, maybe 
because the docking score itself does not take into account the structural features of 
compounds for target assignation of molecule, but simply evaluate the energetic 
profile of the ligand-protein interaction. One of the reasons why this approach gave 
to us a lower capability compared to the original one could be due to the docking 
scoring function. In fact, it does not work the same on all the targets. For this reason 
we wanted to use docking only to consider the molecules poses to recalculate 3D 
descriptors instead of using docking score. 
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Figure 3.4. E%1 (blue) and E%2 (red) related to docking scores 
 
 
New 3D descriptors values (calculated on the docked conformation of ligands) were 
inserted into the matrix of the 7352 compounds and the latter was submitted to 
VLKA algorithm (Conf-VLKA). As last step, the E% scores were calculated again 
on the new scoring and ranking results. The average E%1 related to the lock set 
showed a value of 86%, quite greater than the average E%2 related to test set of 
inhibitors (79.1%). In some cases (11-betaHSD1, BCL2, BCL-xl, CRFR1) E%1 and 
E%2 showed a more evident rise, while other targets such as ALF, GC, MMP-13, 
PDK-1, E%2 resulted in a moderate predictive ability (>60%). 
In Figure 3.5 we report the E% for the new approach. 
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Fig. 3.5 E1% (blue) and E%2 (red) related to 3D descriptors calculated from docking 
poses 
 
In order to avoid analogue redundancies in the ligands set used in this protocol, we 
wanted to assess structural similarity evaluation of compounds. For each target, 
ligand structures were submitted to fingerprint calculations as described in the 
methods section. For the ligand sets analysed, no values higher than 0.75 between the 
structures belonging to the same target set. 
 
The aim of this paper is to compare three different approaches: the original VLKA, 
where molecular descriptors are calculated on in vacuo optimized structures, with 
two more approaches, one based on docking scores and the other exploiting docked 
conformation of ligands for 3D molecular descriptors calculation. 
In the original VLKA approach, the average E%1 achieved the 80.4%, and the E%2 
hit the 78.9%. In some cases (11betaHSD1, AE, BCL-2, CRFR1, DGAT-1, PSP1) 
E%2 yielded a high level of predictive capability (98%). For other biological targets 
(ALF, BCL-xl, CT, DHFR, DOR, GC, GSK3α, PDK-1) E%2 showed lower values, 
but despite this, E% values confirmed a quite good predictive capability (>60.0). 
Only for ALF, this value dropped to 53.1%. In the cases of ABL, ARA1, AROM, 
AURORA-A, CA-4, CDK4, CSP1, DAT, ER-alpha, the obtained data resulted 
interesting because E%2 is higher than E%1. In the second approach, the one based 
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on docking score, the average E%1 and E%2 values were lower than the first above 
mentioned approach, both near to the 60%. Just few target showed prediction 
capability >80% (BCL2, CA-1, and PSP1). 
In the last approach, the conf-VLKA, the average E%1 was 86%, and for many 
targets it rose up at 98%. The average E%2 was 79.1%, just greater than E%2 in the 
original approach. In conclusion, we found that the use of the simple docking score 
for target fishing is not always reliable, maybe because of a caveat of docking scores 
which, is known, are not fully related to the protein-ligand binding energy. Docking 
is much more interesting when used to explore ligand conformations inside the 
binding pocket. In fact, in the last approach, the use of docked ligand conformations 
to recalculate the 3D descriptors and the locks, slightly enhanced the E%1 and E%2 
compared to the original approach (ΔE%1=+6%, ΔE%2=+0.2%). Even though the 
average accuracy of the prediction is similar to the previous one, the most interesting 
data is that for certain targets there was a rise of the E%. For BCL-xl target an 
increase of 11% for the E%1 and a 18%. E%2 were observed. For ER-alpha the 
value of E%1 rose up from 30% to 58% and the variation of the E%2 was only of the 
3%. The best results were observed for MMP-13 (ΔE%1=+41%, ΔE%2=+18%) and 
CDK-4 (ΔE%1=+ 9%, ΔE%2=+6%). Also the PTP-1B target showed a significant 
variation of the E% values with a ΔE%1=+25%, ΔE%2=+14%. 
 
In the light of these considerations, the best results and the strongest variation 
between the old approach and the Conf-VLKA occur for dataset compounds with a 
high degree of branching considered as number of rotamers. This could be justified 
by the fact that the most branched is the molecule the most it will be sensible to 
conformation variations and the best it will be represented by 3D descriptors, as 
demonstrated by Good et al. in 2004 [97, 98]. 
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3.1.4 Conclusions 
 
In this paper, we modified the previous in house developed VLKA protocol in order 
to analyse the ligand conformational effect on the protocol capability, in particular, 
calculating 3D molecular descriptors on the docked conformation of ligands. Our 
VLKA protocol was designed to predict the possible biological target for new 
molecules starting from the structural information contained in molecular descriptors 
calculated on a set of known inhibitors. This first protocol was able to correctly 
predict biological target for the whole dataset with a good degree of reliability (80%) 
[24], and revealed experimentally useful to optimize the biological activity of some 
pyrimidine derivatives [99, 100]. Applying the structure based approach to VLKA 
we observed that, the use of the simple docking scores instead of molecular 
descriptors, revealed not satisfactory results, instead, the Conf-VLKA showed 
slightly better results (86%) than the first VLKA protocol for certain target sets, for 
others no interesting variations were observed. On the light of these considerations, it 
seems like the conf-VLKA approach works slightly better, compared to the previous 
protocol, when applied to targets whose ligands present a highly branched structure. 
According to what already found by Good et al., in a work on the effect of chemical 
structure complexity on molecular descriptors weight for ligand-based virtual 
screening [97, 98]. Another issue to be addressed is that probably the performance of 
the Conf-VLKA is connected to the docking algorithm that works better on some 
proteins more than others. VLKA and Conf-VLKA revealed different strength 
points. While VLKA revealed really fast and immediate to apply, Conf-VLKA, 
although need more computational time, on some proteins revealed a small rise in 
performance, especially for systems in which compounds have a great number of 
torsional bonds and branching. Nevertheless, both approaches (VLKA and Conf-
VLKA) are totally user-defined, so that it is suitable for the use of in vacuo 
descriptors calculation or the descriptors calculation based on binding conformation 
of ligands. This work is a first preliminary study on the ligand conformational effect 
on the VLKA protocol capability. We are now working on the same protocol using 
induced fit docking in order to take into account the target flexibility induced by 
ligands. 
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4. DYNAMIC APPROACH TO VIRTUAL SCREENING  
 
Proteins are constitutionally flexible molecules. They exert their biological function 
undergoing various conformational changes more or less wide. This aspect covers a 
huge importance for the exploration of protein – ligand interactions [50, 101]. The 
receptor and ligand flexibility and the induced conformational changes should be 
considered to correctly estimate the binding mode and the thermodynamics behind 
the binding process [102]. Unfortunately, drug design and virtual screening 
campaigns often neglect these aspects, using a static representation of the protein 
target. Several approaches have been introduced in computational chemistry software 
to take into consideration protein flexibility [103, 104]. The most representative are: 
side-chain flexibility [105], soft docking, induced fit [106, 107] and conformational 
ensemble-based docking [108, 109]. A correct incorporation of protein dynamics for 
drug design is still a challenging task. It has been shown in many cases that including 
protein flexibility leads to higher rates of false positives, since a larger number of 
putative ligands can be accommodated into different conformations of the binding 
pocket [110, 111]. 
Frequently, virtual screening protocols are set up on a conformational ensemble of 
proteins in order to include protein flexibility. Such an approach is based on behalf 
of proteins existing as an ensemble of substates of activation represented by different 
conformations [112, 113]. The main step of this approach is the generation of  
protein conformational ensembles prior to docking and the subsequent binding 
simulation of small molecules within the protein binding pocket of different 
size/shape [114, 115]. However, the approach strongly depends on the sampling 
quality chosen. One of the biggest limitations in using static X-ray or NMR receptor 
structures is that the available experimental conformations may not be sufficient to 
represent suitable conformations of the binding site for correct prediction of 
accommodation of new ligands [116, 117]. Despite the various methods adopted to 
sample protein flexibility, it is still difficult to collect suitable receptor conformations 
to be used prior to virtual screening processes [118, 119]. 
Often, protein conformations are collected starting from MD simulations [120–123]. 
One of the recently developed method to use MD prior to virtual screening is 
presented in the Relaxed Complex Scheme (RCS) approach [124]. Another MD-
based approach is based on the sampling of the Receptor Conformation Ensemble, 
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appropriate for accommodating ligands, which are chemically and structurally 
diverse and thus unbiased toward a particular class of ligands [125]. Recently, this 
approach was successfully employed for ligand profiling of drug metabolizing 
enzymes sulfotransferases. In their work, Martiny et al. adopted docking on RCE 
generated by MD simulations, combined with hierarchical conformational clustering 
of different binding site conformations [126]. 
Another interesting approach, adopted by Rueda et al. is to explore collective 
movement-based conformational changes [127]. In his work, Rueda exploits cross-
docking on the ensemble structures generated by MD. In the last years, receptor 
flexibility has been also assessed using a potential grid representing the receptor 
deformed through selected collective movements and global structural changes 
following ligand binding [128]. However, considering a large number of modelled 
conformations may sometimes lead to less predictive VS results compared to those 
obtained by using the best performing crystal or NMR structures, due to the possible 
generation of non-native protein-ligand conformations [129, 130]. 
Applying these concepts to structure-based pharmacophore screening, it is important 
to point out that the pharmacophore model is sensitive to the atomic coordinates of 
the protein-ligand complex from which it was derived The first issue is closely 
linked to the source of the coordinates for the protein-ligand complex, whose 
coordinates are usually taken from the Protein Data Bank (PDB) [93]. Very often, 
the protein structures solved by X-ray crystallography may be affected by errors such 
as crystal contacts and solvent effects; for this reason, the reliability of protein-ligand 
coordinates has been frequently questioned [131, 132]. Proteins and small molecules 
are inherently dynamic and undergo a wide range of motions, ranging from the 
vibrations of individual bonds to collective, large structural movements. The crystal 
structure of the protein-ligand complex represents only a single snapshot of a 
dynamic system, providing neither information about the conformational flexibility 
of the ligand, nor about motions of the residues in and near the binding pocket [133, 
134]. Thus, pharmacophore models derived from such structures might include 
features that are artefacts, caused either by crystal packing effects or by the single set 
of coordinates of the structure.  Moreover, these PDB-derived pharmacophore 
models could contain too few or too many features resulting in a limited use. 
Increased number of pharmacophore features are normally accompanied by a loss of 
sensitivity, and usually pharmacophore models composed of more than seven 
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chemical features are not suitable for database screening [135]. In this regard, the 
most important issue becomes the choice of reliable criteria to prioritize them. In the 
last years, several efforts have been made to integrate the natural dynamic behaviour 
of proteins in pharmacophore models. One proposed approach was based on the 
multi-complex pharmacophore models. Here, the models were derived from multiple 
crystal structures of the same protein in contact with different small molecules. 
Protein-ligand interaction patterns were extracted from the available structures and 
merged in pharmacophore maps [135, 136]. This approach, however, is limited to 
proteins for with multiple crystal structures are available and which have the same 
binding mode: it does not really consider the dynamics of the ligand-protein 
complex. 
One very general way to avoid dependence on a single set of coordinates is the use of 
molecular dynamics (MD) simulations to generate multiple sets of coordinates and 
use these as the basis for pharmacophore models. MD simulations have proven 
invaluable to understand the dynamics of biomolecules [137–139]. Several 
approaches have been proposed to generate trajectories of protein-ligand complexes, 
subsequently clustered to extract representative structures as reliable pharmacophore 
models. [140, 141]. Most recently, Choudhury et al. presented a new way to build 
pharmacophore models from MD simulation. For each structure saved during MD 
simulations, one pharmacophore was generated and then ranked based on docking 
and screening results [60]. 
In the next chapters of this PhD thesis, I will present the chronological pathway of 
the study carried out to explore the use of a new approach to the pharmacophore 
screening: The Dynamic Pharmacophore. 
In Chapter 4.1 I will present the results of a method based on the application of the 
MD prior to the pharmacophore modelling [142]. In Chapter 4.2 I will describe an 
approach based on the most frequent pharmacophore features retrieved from MD 
simulations and then adopted as pharmacophore model [143]. In Chapter 4.3 the 
application of the “most frequent features” method to the study of the IGF-1R 
(insulin-like growth factor-1 receptor) kinase domain is reported [144].  
Finally, chapter 4.4 will concern an innovative approach to the dynamic 
pharmacophore model, based on a different starting point compared to those 
discussed in the previous chapters. Several PDB crystal structures were explored, 
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containing different ligands, to check the occurrence of a common interaction pattern 
and maintained during the MD simulations[145]. 
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4.1 Comparing pharmacophore models derived from 
crystal structures and from molecular dynamics simulations 
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4.1.1 Introduction  
!
The aim of this study was to compare pharmacophore models obtained from the 
crystal structure of a ligand-protein complex with the pharmacophore models derived 
from the last frame of a molecular dynamics (MD) simulation. The pharmacophore 
model obtained from the crystal structure of a ligand-protein complex was called 
“initial pharmacophore model”, models created from the last frame of the MD 
simulation has been defined as “MD pharmacophore models”. Considering the final 
structure of a given MD simulation is the most basic MD-refined structure 
refinement protocol. Even though the approach is simple, it can resolve some of the 
problems connected to protein-ligand structures obtained from X-ray crystallography 
[146–148]. In our opinion, the comparison between the initial pharmacophore model 
and the MD-refined models can give some crucial information for constructing a 
reliable pharmacophore models [142]. 
In this work we investigated two main issues: 
1.)! Is there any difference in terms of number and type of pharmacophore 
features comparing the crystal structure derived model with the MD-refined model? 
2.)! Is there a difference in the ability of the initial pharmacophore model and the 
MD-refined pharmacophore model to distinguish between active and decoy 
compounds? 
The first question was answered by visual inspection of the obtained pharmacophore 
models. To answer the second question we screened active/decoy databases of the 
investigated protein-ligand complexes to calculate receiver operating characteristic 
(ROC) curves and enrichment factors [149, 150]. 
We analysed 6 different protein ligand systems (PDB CODE: 1J4H, 3BQD, 2HZI, 
3L3M, 1UYG and 3EL8). Structures were chosen from the DUD-E database. This 
database provides datasets of known actives and calculated decoys for protein-ligand 
complexes. From these complexes using selection criteria that were governed by 
system size, number of ligands present and kind of ions in complex with the ligand 
or protein [151].  
The virtual screening process was used starting from the pharmacophore model as a 
query for classification of compounds into decoy and active compounds, assigns 
score values and constructs a sorted list of these compounds using the score as key. 
The number of true positive compounds retrieved using a specific pharmacophore 
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model as opposed to the number hypothetically found if compounds were screened 
randomly was expressed as Enrichment Factor (EF) [152, 153] as defined in Eq. 
(4.1). 
 
 
 
(Eq.4.1) 
Where: tphitlist is the number of true positive in the hitlist; 
fphitlist corresponds to the number of false positive in the hitlist; 
NA and ND are the number of active and decoy compounds in the testset. 
 
Enrichment factors can range from 1 - molecules are sorted randomly - to > 100, 
which means that only a small percentage of the order list needs to be screened in-
vitro to find a large number of active molecules [149]. 
 
4.1.2 Materials and Methods 
!
PDB quality control 
The quality and correctness of the PDB structures was audited using the Quality 
Control server [154]. Modeller 9.15 was used if residues were missing [155]. 
Subsequently all structures were analysed with PropKa 3.1 in order to check the 
protonation state of the protein and the ligand [156, 157]. 
Molecular Dynamics 
CHARMM-GUI was used to set up the simulations and the CHARMM software 
package to run them [158, 159]. The CGenFF and paramchem was used to obtain 
parameter and topology files for the small molecules [160, 161]. For all the 
CHARMM/openMM version was used to run molecular dynamic simulations for 6 
protein-ligand complexes [162]. The systems were solvated in rectangular water 
boxes with TIP3P water molecules. Electrostatic interactions were computed by the 
particle-mesh-Ewald method. From the starting structures we carried constant 
pressure, constant temperature MD simulations (Berendsen thermostat and barostat). 
The length of each simulations was 20 ns; the time step was 2 fs and SHAKE was 
used to keep all bonds involving hydrogen atoms fixed. Before each simulation we 
equilibrated the protein-ligand-water system for 25ps with a time step length of 1fs. 
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RMSD calculation 
The RMSD was analysed using the python package MDAnalysis [163]. For the 
protein the RMSD of the C-alpha atoms was calculated and for the ligand the RMSD 
of all heavy atoms was calculated against the initial PDB structure. Target and 
reference structures were aligned on C-alpha atoms before the RMSD was 
calculated, the ligand was not independently aligned. 
LigandScout 
For generating structure-based pharmacophore models and screening libraries 
LigandScout 4.09.1 was used. Screening was performed using the command line tool 
iscreen provided by LigandScout [164]. The screening database for the protein 
systems were generated using the decoys and actives from the DUD-E database 
[151]. 
 
4.1.3 Results and Discussion 
!
Quality control of protein-ligand structures  
For one protein (3EL8) it was necessary to add missing residues. Using the software 
Modeller 13 residues from residue number 411 to 423 were inserted [155]. The 
amino acid sequence was obtained from the DNA sequence of the protein from the 
NCBI database [165]. The protonation state and side chain orientation was set in 
accord with propka [156, 157] and the Quality Control Check provided by the Joint 
Center for Structural Genomics [154]. 
RMSD 
For all protein-ligand systems the root mean square deviation (RMSD) for the 
protein and the ligand was independently calculated and is shown in Fig. 4.1. The 
ligand and the protein RMSD values were calculated with the aligned C-alpha atoms 
of the target and reference structure. 
The RMSD of the protein and ligand was analysed to detect large scale movements 
of the protein or the ligand. In addition, we used the deviation of the ligand to 
determine if the ligand reaches a stable binding state. The RMSD plots of the 
different ligands show very similar behaviour. The RMSD usually changes in the 
beginning to an average value from which the ligand deviates only marginal. This 
transition happens fast, e.g. 2HZI reaches the average value of 1.03 Å in less than 0.1 
ns and has a standard deviation of 0.2 Å from the mean. The ligand of 1J4H is the 
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only exception - it takes nearly 2.5 ns to reach the stable plateau around the average 
value of 1.58. 
For the protein the behaviour of the RMSD was in the range of normal conduct 
during a MD simulation. 
 
 
Fig 4.1 The root mean square deviation (RMSD) of the protein (in red) and the 
ligand (in blue) is provided as a function of time for the six analyzed protein-ligand 
complexes. The RMSD is calculated against the aligned PDB structure. The protein-
ligand complex is aligned based on the protein backbone. For all systems the ligand 
and the protein experiences a rapid RMSD deviation from the original structure of at 
least 0.5 Angstrom (Å). The different RMSD ranges on the y-axis should be noted. 
 
Comparing pharmacophore models 
In Fig. 4.2 the 2D view of the ligand together with the assigned pharmacophore 
features is reported. The pharmacophore model obtained from the PDB file and the 
MD-refined pharmacophore model are shown for every protein-ligand system. 
For all analyzed systems the initial pharmacophore model and the MD-refined 
pharmacophore model differs. Of the six analysed systems the amount of 
pharmacophore features for the initial model decreased in three cases, in one case the 
amount of features (but not the kind of features) stayed the same and in two cases the 
amount of features increased compared to the pharmacophore model obtained with 
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the MD-refined pharmacophore model. Looking at specific feature types it is 
interesting to note that hydrophobic features do not change in amount nor in involved 
atoms. In contrast none of the aromatic features are present in the MD-refined 
pharmacophore model. Most of the variability in the pharmacophore features was 
found to be due to hydrogen bond acceptors and donors. 
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cont. 
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Fig 4.2 Comparing the initial pharmacophore model and the MD-refined 
pharmacophore model. The features in yellow indicate hydrophobic features, the 
vector features in read indicate hydrogen bond acceptors, the vector features in 
green indicate hydrogen bond donors, the feature spheres in blue with associated 
vectors indicate aromatic features and the features in blue with multiple lines 
associated indicate salt bridges. 
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Virtual screening results 
In Fig. 4.3 the ROC curves for the different protein-ligand systems are shown. 
For 1J4H the initial pharmacophore model and the MD-refined pharmacophore 
model cannot distinguish between actives and decoys. 
For 1UYG the MD-refined pharmacophore model can distinguish between active and 
decoy compounds. With one omitted feature the overall ability to separate actives 
and decoys is better than with zero omitted features, but the enrichment factor for the 
first percent is lower. The initial pharmacophore model with zero omitted features 
can distinguish between active and decoy compounds for the first percent of the 
results, but above the 5% mark it favors decoys over actives. The model with one 
omitted features has among the top ranking results only false positive compounds but 
after the 1% mark it favors actives over decoys. 
The MD-refined pharmacophore model for 2HZI favors active over inactive 
compounds for zero, one and two omitted features. This is not always visible in the 
ROC curve but looking at the enrichment factor it becomes clear that even the 
pharmacophore model with zero omitted features favors actives. The model with one 
omitted features favors actives only in the highest ranking results, the model with 
two omitted features favors actives for all results. The initial pharmacophore model, 
with one and two omitted features, favors actives. 
For 3BQD the MD-refined pharmacophore model with one and two omitted features 
has a high enrichment factors (27.9 and 20.2 for 100%) as well as the initial 
pharmacophore model with one or two omitted features of 18.6 and 6.6 for 100%. 
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Fig 4.3  
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Fig 4.3 The receiver operating characteristic (ROC) curve for the different protein-ligand systems is shown. The true positive rate is 
seen on the Y axis and the false positive rate on the X axis. The number next to the PDB code indicates the number of omitted 
features: 0 means that no features were omitted, 1 or 2 means that either one or two features were omitted during the screening. In 
the plots the number of total hits, the area under the curve (AUC) and the enrichment factor (EF) is shown at 1%, 5%, 10% and 
100%. For 3EL8 the MD-refined pharmacophore model with one and two omitted features has high enrichment factors (10.8 and 3.3 
for 100%) whereas the initial pharmacophore model with zero or one omitted features has no preference for actives, with two 
omitted features the model has a slight overall preference for active compounds (ER: 1.7 for 100%) 
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The MD-refined pharmacophore model for 3L3M with zero omitted features has an 
overall preference for actives, but this effect is only marginal. The same model with 
one omitted features has a significant early enrichment but the sensitivity decreases 
after the 5% mark. The initial pharmacophore model with zero omitted features is not 
able to return any results, with one omitted feature the model has a good early 
enrichment (23.7%) with constant sensitivity. 
The screening results obtained from the MD-refined pharmacophore model and from 
the initial pharmacophore model are different. With the exception of 1J4H, for which 
both pharmacophore models performed badly, either the refined pharmacophore 
model or the initial pharmacophore model were able to favor active compounds over 
inactive ones - in some cases e.g. 3BQD both were able to distinguish between the 
groups. Depending on the preferred result (early enrichment vs overall enrichment 
factor) the interpretation of the overall performance of the two approaches can vary. 
Simply looking at early enrichment (considering only the enrichment factor above 
1% of the total compounds) the pharmacophore model obtained with the MD-refined 
pharmacophore model performs better for 1UYG, on average for 2HZI, for 3BQD 
and for 3EL8. The initial pharmacophore model performs better for the screening on 
the compounds for 3L3M. 
Considering the enrichment factor at 100% of analysed compounds the MD-refined 
pharmacophore model performs better for 1J4H (even though still badly), on average 
for 1UYG, on average for 2HZI, for 3BQD. In the analysed cases the overall 
enrichment factor mirrors the results obtained from the early enrichment results. 
 
4.1.4 Conclusions 
!
The findings reported in this work suggested that the refinement of pharmacophore 
models using molecular dynamic simulations is an important starting point for better 
exploring ligand protein interactions. Even very simple structure refinement 
approaches, like the reported one, lead to pharmacophore models that return on 
average better screening results. 
Additional interaction information can be unveiled analysing the dynamic behaviour 
of protein and ligand and harvesting these information can lead to better 
pharmacophore models that can target specific binding sites or interact with 
transitional conformations. For this reason in the future we aim to deepen the real 
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dynamics of the pharmacophore feature assessing a study of the time evolution and 
frequency of the encountered features, this is so far, to our knowledge, an approach 
still not investigated by the computational chemists. 
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4.2 Evaluating the stability of pharmacophore features 
using molecular dynamics simulations
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4.2.1 Introduction 
!
In this work we investigated the dynamics and the stability of the structure-based 
pharmacophore out of 12 protein-ligand complexes. Starting from an MD simulation 
a pharmacophore model for each structure produced during the simulation was 
generated. Through the creation of a called merged pharmacophore model we took 
into consideration all features that are seen either in the experimental structure (PDB 
X-ray structure) or any of the snapshots generated during the MD simulation. Thus, 
it incorporates the dynamics of the protein—ligand complex. The frequency with 
which individual features could be a useful way to prioritize the features if needed 
and to detect which ones only appear rarely. 
For each system, a 20ns simulation in aqueous solution was carried out, and a 
merged pharmacophore model was derived as just outlined. In this proof-of-concept 
work we focus foremost on exploring three key questions concerning the viability of 
our approach. 
1.! What are the differences between the traditional pharmacophore models 
constructed from the PDB structures (the PDB pharmacophores) and the merged 
pharmacophore model? 
2.! Are the features arising most frequently during the MD simulation also 
present in the PDB pharmacophore model? 
3.! In addition to answering the first two questions for each of the complexes 
studied, we also explore how the four principal types of pharmacophore features 
(hydrophobic features, aromatic features, ionizable group features and hydrogen 
bond features) behave in this respect. 
As mentioned before, the information about pharmacophore feature frequencies may 
aid in prioritizing features. For example features that are present in the 
pharmacophore model derived from the PDB structure, but occur only rarely during 
the MD simulation (e.g., less than 5% of the time) might represent artifacts and 
should possibly be discarded. Conversely, features that are not present in the PDB 
structure, but appear very frequently during the MD simulation (e.g., more than 90% 
of the time) should be regarded as important. Even though the frequency information 
alone may not be enough to rank features, it can help make an informed decision 
which features to keep/add and which to ignore, particularly if a pharmacophore 
model has too many features. 
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4.2.2 Materials and Methods  
 
For this study twelve different protein-ligand complexes were selected from the 
PDB: 1J4H, 1XL2, 2HZI, 3L3M, 1UYG, 3EL8, 2GTK, 2P54, 3BQD, 2AZR, 2OJ9 
and 2OJG. The choice of complexes was somewhat arbitrary, though guided by the 
following considerations: system size (solvated protein-ligand complex less than 
70,000 atoms), only a single ligand, no metal ions involved in the binding. The 
complexes will be referred to by their PDB code. The following terminology will be 
used. The pharmacophore model obtained based on the experimental structure is 
referred to as PDB pharmacophore model, features specific to a PDB model as PDB 
features. In the merged pharmacophore model all observed pharmacophore features 
are mapped on the ligand, the merged model includes features present in the crystal 
structure, as well as features occurring during the MD. Features not present in the 
crystal structure, i.e., seen only during the MD simulation, will be referred to as MD 
derived features. 
PDB quality control 
The quality and correctness of the PDB structures was audited using the Quality 
Control server [154]. Modeller 9.15 was used if residues were missing [155]. 
Subsequently all structures were analysed with PropKa 3.1 in order to check the 
protonation state of the protein and the ligand [156, 157]. 
Molecular Dynamics 
We used CHARMM-GUI to set up the simulations and the CHARMM software 
package to run them [158, 159]. The CGenFF and paramchem was used to obtain 
parameter and topology files for the small molecules [160, 161]. For all the 
CHARMM/openMM version was used to run molecular dynamic simulations for 6 
protein-ligand complexes [162]. The systems were solvated in rectangular water 
boxes with TIP3P water molecules. Electrostatic interactions were computed by the 
particle-mesh-Ewald method. From the starting structures we carried constant 
pressure, constant temperature MD simulations (Berendsen thermostat and barostat). 
The length of each simulations was 20 ns; the time step was 2 fs and SHAKE was 
used to keep all bonds involving hydrogen atoms fixed. Before each simulation we 
equilibrated the protein-ligand-water system for 25ps with a time step length of 1fs. 
RMSD calculation 
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The RMSD was analysed using the python package MDAnalysis [163]. For the 
protein the RMSD of the C-alpha atoms was calculated and for the ligand the RMSD 
of all heavy atoms was calculated against the initial PDB structure. Target and 
reference structures were aligned on C-alpha atoms before the RMSD was 
calculated, the ligand was not independently aligned. 
Pharmacophore generation 
For generating structure-based pharmacophore models and screening libraries 
LigandScout 4.09.1 was used to generate a structure based pharmacophore model for 
each frame saved during the MD simulation (2000 pharmacophore models) and for 
the PDB structure [164]. 
The resulting 2001 pharmacophore models for each protein—ligand complex were 
analyzed as follows. Each pharmacophore feature has two properties: the ligand 
atoms that are part of the feature and the feature type. If both properties of a 
pharmacophore feature were present in two models, then this feature was considered 
identical and the frequency count of this specific feature was incremented. In this 
manner we obtained statistics how often a certain feature was present during the 
course of the MD simulation. Separate statistics were made for features not present 
in the PDB pharmacophore model, i.e., features only seen during the MD simulation. 
Using this frequency information, the merged pharmacophore model encompassing 
all features seen during the simulation was constructed by mapping the features on a 
representative 2D and 3D structure of the ligand. 
 
4.2.3 Results and Discussion 
!
All trajectories were inspected visually to ensure that no large scale movement took 
place and that the ligand remained within the binding side at all times. For all twelve 
systems, the RMSD of the Cα-atoms was in an acceptable range. The same was true 
for most ligands, except for 2OJ9 and 2OJG. In the case of 2OJ9, the imidazole and 
pyridine moieties of the ligand rotated freely during the MD simulation, causing an 
average ligand RMSD of 5.6 Å. Similarly, the dimethylamino and phenyl group of 
the ligand in 2OJG was highly flexible. Nevertheless, even in those two cases the 
protein-ligand complexes were stable during the simulation. 
In Fig. 4.4 the merged pharmacophore models of all twelve systems are shown. The 
models contain all encountered features, and the frequency (in percent) with which a 
feature occurs is given (the numbers in the small boxes in Fig. 4.4). This schematic 
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representation provides an overview of the stability / robustness of the individual 
features in the twelve complexes. 
 
 
Fig.4.4 Merged pharmacophore models mapped on the 2D representation of the 
ligand for all twelve protein-ligand systems studied. Individual figures are labeled by 
the PDB code. Feature types are color-coded as follows: yellow spheres indicate 
hydrophobic features (H), grey/white chessmate spheres indicate aromatic 
interactions (AR), small green spheres indicate hydrogen bond donors (HBD), small 
red spheres indicate hydrogen bond acceptors (HBA), blue spheres indicate 
positively ionizable groups (PI), and big pink spheres indicate negatively ionizable 
groups (NI). The numbers in boxes indicate the frequency in percent with which a 
feature is found in each of the individual pharmacophore models from which the 
merged model was constructed (cf. Methods). The box color indicates the feature 
type: H (yellow), AR (black), HBA (light green), HBD (red), PI (blue), NI (pink). 
Filled boxes indicate features not present in the crystal structure, i.e., which appear 
only in the course of the MD simulation 
 
Even a cursory inspection of Fig 4.4 shows that in all protein-ligand systems there 
are MD derived features, i.e., pharmacophore features which appear during the MD 
simulations; these are indicated by the shaded background of the boxes listing the 
frequency information. The number of the MD derived features, however, varies 
considerably, from one in, e.g., 2HZI up to five in, e.g., 2P54. Similarly, MD derived 
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features can occur very rarely (less than 5% of the time), see, e.g., 1J4H, as well as 
very frequently (more than 90% of the time), e.g., 2GTK. 
The merged pharmacophore models shown in Fig 4.4 can be roughly divided into 
two groups: (1) pharmacophore models, for which the MD simulation added little 
new information, i.e. any MD derived features had low frequencies, and (2) 
pharmacophore models, for which MD simulation revealed information that can be 
helpful for further work with the models, i.e. the model has PDB features that 
disappeared completely during the MD simulation or occurred only infrequently and 
MD-derived features that appeared with high frequencies. 
We considered 2HZI, 1J4H, 3L3M, 2AZR and 2P54 to be members of group (1). All 
of them display high frequencies for most PDB features and low frequencies for 
MD-derived features. In particular, 2HZI and 1J4H are prototypical members of this 
first group: only one (2HZI) or two (1J4H) MD derived features were observed, and 
their frequencies were very low. By contrast, the assignment of the other three 
complexes to group (1) was a bit more ambiguous. E.g., there were eight MD derived 
features in 3L3M, and one PDB feature only had a frequency of 17% during the MD 
simulation. However, all MD derived features were observed very rarely (1-8%), and 
the “low-frequency” PDB feature is an aromatic feature. As will be discussed below, 
aromatic features in general tended to occur with low frequencies during the MD 
simulations; thus, 17% is a relatively high value for an aromatic feature. Because of 
this, we feel that 3LM1 is best assigned to group (1); in the case of 2AZR and 2P54, 
the situation is similar. 
We considered 2OJG, 3BQD, EL8, 1XL2, 2OJ9, 2GTK and 1UYG to belong to 
group (2). All of them have either PDB features that occur rather infrequently during 
the MD simulation (1XL2, 2OJ9), MD-derived features with high frequencies 
(2OJG, 3BQD) or both (3EL8, 1UYG, 2GTK). 
Two examples for group (2) should be considered in detail: the pharmacophore 
model for 2OJ9 and 2OJG. The pharmacophore model for 2OJ9 has one hydrogen 
bond acceptor and one hydrogen donor PDB feature with frequencies below 25%. 
The three other PDB features - all of them hydrophobic features - have frequencies 
above 90%. There are six MD-derived features. While one of the MD-derived 
hydrogen bond donor features has is seen more than 50% percent of the time, the 
other MD-derived features have low frequencies. For this pharmacophore model the 
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MD simulation shows that some of the initial PDB features are not stable during the 
MD simulation. 
The pharmacophore model for 2OJG has only two PDB features, one hydrophobic 
and one hydrogen bond donor feature, whereas the merged model contains three 
additional MD-derived features (one additional hydrogen bond donor feature and two 
hydrogen bond acceptor features). All three had a high frequency of occurrence 
(>70%). Their absence in the PDB pharmacophore model may have been caused by 
an unfavorable pose of the ligand in the binding pocket of the crystallized protein. 
The members of groups (2) provide good examples how dynamics influences the 
pharmacophore hypothesis. On the one hand, PDB features which exhibit low 
frequencies during the MD simulation could be artifacts of the initial protein-ligand 
coordinates. If these features are kept for virtual screening, they could result in 
erroneous/misleading hits. On the other hand, MD derived features can be essential 
to construct a usable pharmacophore model. With the PDB pharmacophore model of 
2OJG virtual screening would not be possible since a minimum of three features are 
normally necessary. By contrast, the merged model with five features would provide 
a usable starting point for virtual screening. While Fig 4.4 illustrates the effect of 
dynamics on the individual pharmacophore models of the twelve complexes studied 
here, Table 4.1 summarizes the behavior of feature types during the MD simulations. 
For each of the six basic pharmacophore feature types (hydrophobic (H), hydrogen 
bond acceptor (HBA), hydrogen bond donor (HBD), negatively ionizable (NI), 
positively ionizable (PI), and aromatic (AR), first the total (=cumulative) number of 
occurrences in all twelve merged models is listed in Table 4.1 (column 'Merged 
features, total'). This number is then broken down into features present in the PDB 
model (columns 'PDB features' in Tab.4.1) and features only seen during the MD 
(columns 'MD derived features'). For each of these two groups, the total number of 
occurrences, as well as the numbers of occurrences present >90% and >50% of the 
simulation time are given. 
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Table 4.1. Overall occurrence of pharmacophore feature types in the 12 systems 
studied. 
 
a) For the meaning of abbreviated feature types see Fig. 4.4 
b) Total count how often a feature type occurs. 
c) Number of instances of a particular feature type present >90% during the MD simulation. 
d) Number of instances of a particular feature type present >50% during the MD simulation. 
 
Overall, PDB features appear more stable than MD derived ones. If one sums up all 
entries in column 'PDB features, >50%' of TAB 1 and compares to the sum of 
column 'PDB features, total', one finds that 79% (67 out of 85) of the PDB features 
are present 50% or more during the MD simulation. The same calculation for MD 
derived features gives 24% (12 out of 50). This distinction becomes even more 
pronounced if one repeats this analysis for all features present >90% during the MD 
simulation, which gives 66% for PDB features vs. 10% for MD derived features. 
However, at the same time Table 4.1 illustrates that dynamics affects the various 
feature types quite differently. Consider e.g., aromatic features (AR). There are 
significantly more MD derived aromatic features (9) than aromatic PDB features (4). 
Both of them occur rather infrequently, i.e., for AR all entries in columns >50% and 
>90% are zero (last line of TABLE 4.1). The reverse situation is found for 
hydrophobic features (H). Here, there are substantially more PDB than MD-derived 
features, and, particularly in the PDB case, the robustness of the feature is high (40 
out of 43 hydrophobic PDB features are present >90% of the time). 
The AR and H features are the most extreme examples, the other four feature types 
(HBA, HBD, NI, PI) lie between these two. Clearly, aromatic features appear much 
more sensitive to small changes resulting from the motions of ligand and protein 
during the MD simulation compared to hydrophobic features. Hydrogen bond 
acceptor and hydrogen bond donor types follow the hydrophobic type in terms of 
prevalence. Similarly to the hydrophobic features, the stability of the PDB features is 
higher than for the MD-derived features. More than 70% of the PDB hydrogen bond 
features (HBA and HBD together) belong to the >50% group; for the MD-derived 
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hydrogen bond features this number drops to 22%. However, there are slightly more 
MD-derived hydrogen bond features (32) than PDB hydrogen bond features (31). In 
particular, the number of MD derived HBA features (25) is larger than that of the 
PDB HBA features. 
The differences in stability between feature types have much to do with the 
definitions of / criteria for the various feature types. 
The low frequency of the aromatic features is the consequence of the rules used to 
classify them: The geometric constraints on the aromatic ring plane are easily 
violated by flexible aromatic rings, e.g., rings that can rotate; furthermore, the rule 
set that atom groups on the protein side have to fulfil to be regarded as counterpart of 
an aromatic interaction are rather strict. 
The relatively large number of MD-derived HBA features is the result of the 
chemical nature of the ligands (most ligands have multiple groups that can act as 
hydrogen bond acceptors) and the definition of hydrogen bond interactions. 
LigandScout uses angle and length criteria for the classification of hydrogen bond 
features; i.e., the interaction partner must be within a specified angle range and 
nearer than a certain distance threshold [164]. Thus, on the one hand, the constraints 
for hydrogen bond features are more rigorous compared to the hydrophobic feature, 
and a miniscule change in geometry can toggle whether an acceptor-donor pair is 
classified as a hydrogen bond or not. Consequently, the dynamical behavior of 
hydrogen bond features is different than that of hydrophobic features (data not 
shown). On the other hand, the amino acids acting as potential interaction partners 
for hydrogen bond acceptor features (threonine, tyrosine, lysine, cysteine, glutamine, 
serine, histidine, arginine) have mostly small atom groups that can rotate and move 
during the MD simulation. Thus, while a particular hydrogen bond is broken, the 
partner on the protein side can be often easily replaced by another amino acid. 
In contrast the high stability of the hydrophobic features is also the consequence of 
the rules governing the classification as a hydrophobic feature. Specifically, in 
LigandScout, the interaction partner on the macromolecular side can be located 
anywhere between 1.0 and 5.9 Å away, and the requirements for atom groups on 
ligand and protein side to be considered part of a hydrophobic interaction are rather 
unspecific [164]. Finally, there is a small number of ionizable features present in the 
systems studied (four NI, two PI). Again, the stability of this features can be 
regarded as a consequence of the feature definition used. For a ionizable group in the 
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ligand to be considered an ionizable feature, LigandScout requires the presence of an 
opposite ionizable group on the macromolecule side within a distance of 1.5 to 5.6 
Å. Given this generous constraint, this feature will be present during most of the 
simulation time, provided a counterpart is available at all [164]. 
 
4.2.4 Conclusions 
!
We have shown that different pharmacophore feature types display varying stability 
during the MD simulations. On average PDB features are more stable than MD-
derived features, but there are notable exceptions. These exceptions represent 
pharmacophore features that are not accessible using only the PDB structure and in 
one example (2OJG) these additional feature were necessary for further work with 
the pharmacophore model. 
We believe that the presented results indicate that the frequency information 
obtained using MD simulation can be used to refine the pharmacophore model 
(add/remove features) - yet we acknowledge the fact that frequencies between 
different feature types might not be comparable, at least not on a linear scale. Using 
these results as a first step we will continue our work on this topic and will 
investigate the possibility of pharmacophore model refinement using information 
obtained through MD simulations. 
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4.3  Pharmacophore models derived from molecular 
dynamics simulations: A case study 
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4.3.1 Introduction  
!
In the previous chapter we investigated the possibility of improving pharmacophore 
model using molecular dynamic simulations to get the most frequent pharmacophore 
features. In this case study we present preliminary results that extend the analysis to 
one protein-ligand system for virtual screening. We analysed the variability of the 
interaction partners of the pharmacophore model and analyse the occurrence of 
features as a function of time. From this analysis two pharmacophore models are 
derived based on the frequency of interactions and the time resolved dynamics of the 
pharmacophore features. 
The used protein-ligand complex was the PDB code 2OJ9 and represents the crystal 
structure of the IGF-1R (insulin-like growth factor-1 receptor) kinase domain in 
complex with a benzimidazole inhibitor. Overexpression of IGF-1R has been 
demonstrated in a variety of tumors, including glioma, lung, ovary, breast, 
carcinomas, sarcomas, and melanoma [166]. This protein-ligand complex was 
chosen from the analysed complexes in [143] because the pharmacophore model 
contains a balanced number of the most common features (3 hydrophobic features, 3 
hydrogen bond donor features, 2 hydrogen bond acceptor features, 3 aromatic 
features). 
Typically, most ligands of protein kinases bind in the hinge region at the folding cleft 
of the N- and C-lobes. Common scaffolds that bind this region contain two hydrogen 
bond features, usually a donor-acceptor pair that interact with the hinge backbone. 
The PDB pharmacophore model displays the typical hydrogen bond interaction 
pattern with MET103 and GLU101, as described in the literature [166]. 
As fully described in our published paper [143], starting from MD simulation, every 
10 ps the coordinates were saved resulting in 2000 coordinate sets, we also 
considered the initial PDB one. A pharmacophore model was derived from each 
structure that was obtained during the MD simulation. For further analysis a 
consensus pharmacophore model (a merged pharmacophore model) was generated 
which consists of all features that are present either in the experimental structure or 
in any snapshot generated during the multiple MD simulations, thus it incorporates 
information about the dynamics of the protein-ligand complex. The frequency with 
which individual features are present permits to rank/prioritize the features if needed 
and to detect outliers, i.e., features seen only rarely. Additionally, the interaction 
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partners for each pharmacophore feature were analyzed and an interaction map 
(interaction matrix) was constructed. An interaction maps allows to quantitatively 
analyze the interaction partners of pharmacophore features. As a final step the 
frequency of the pharmacophore features was analyzed as a function of time. 
Combining these different analysis methods for the dynamics of the pharmacophore 
features make allows to consciously derive pharmacophore models that are different 
than the corresponding model obtained with the PDB structure. Starting from the 
merged pharmacophore model, we run a virtual screening using an active and decoys 
database retrieved from DUD-E [151]. 
 
4.3.2 Materials and Methods 
!
For the MD simulation methods and Pharmacophore generation I refer to the original 
papers describing the method [143] or to the previous chapter. 
Virtual Screening:  
Virtual screening was performed using known active and calculated decoy molecules 
obtained from the DUD-E database [151]. The database provided 226 actives and 
9395 decoys. All molecules were prepared as libraries for the screening using the 
command line tool idbgen provided by LigandScout. Conformers were generated 
using the icon best option in idbgen, this option produces a maximum number of 200 
conformations for each molecule processed. 
Interaction matrix generation: 
The columns of the interaction matrix indicate all amino acid residues that are 
involved in a pharmacophore feature at some point during the MD simulations, the 
rows designate all pharmacophore features and the values in the matrix indicate how 
often a specific amino acid was involved in a specific pharmacophore feature. In this 
way it is possible to analyze the number of interaction partners and also their 
statistical frequency. The numeric values were coded as a heat map – the colors 
range from blue (zero interaction) to dark red (interaction at every time step). The 
numeric values for hydrogen bond and aromatic interactions are given explicitly in 
the heat map for values below 400. The interaction map was generated using the 
python package matplotlib [167]. 
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Frequency Plot generation: 
For the MD simulations a frequency plot is calculated. This plot shows the 
occurrence of the features as a function of time. This is calculated as follows: The 
pharmacophore models are chronologically sorted and for every pharmacophore 
feature an occurrence list is calculated. Every time a pharmacophore model at a 
specific time step displays a specific feature 1 is inserted at the time step defined 
position in the list, otherwise 0 gets inserted. This results in a list with 2001 entries 
for every pharmacophore feature, which contains zeros and ones. In the end these 
lists are reduced by summing over chunks of 100 entries – resulting in a new list with 
20 entries containing numbers between 100 and 0. To obtain a graphical 
representation, these lists are subsequently plotted using the python package 
matplotlib. 
 
4.3.3 Results and Discussion  
!
The trajectory of the protein-ligand complex was visually inspected to ensure that no 
large scale movements took place and that the ligand remained within the binding 
site at all times. The root mean square deviation (RMSD) values of the Cα-atoms of 
the protein were in an acceptable range (the RMSD plot for the ligand and protein 
backbone is shown in Fig. 4.5). In contrast, the RMSD values of the ligand are rather 
high (ranging to a maximum of 9 Angstrom). 
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Figure 4.5. The root mean square deviation (RMSD) in Angstrom (Å) of the protein 
backbone (in blue) and the ligand (in red) as a function of time for the analysed 
protein-ligand 
 
In Fig. 4.6 representative structures for the first (Fig. 4.6 (1)) to the fourth quarter 
(Fig. 4.6 (4)) of the MD simulation are shown. As can be seen the pyridine moieties 
of the ligand rotates freely during the MD simulation, but also the translation of the 
imidazole contributes to the elevated RMSD values. Nevertheless, the protein-ligand 
complex was stable during the simulation. 
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Figure 4.6. The ligand inside the binding pocket is shown at 4 different timesteps. 
The length of the MD simulation is divided in 4 equally long parts and clustering is 
performed based on the RMSD of the ligand. A representative ligand structure is 
extracted from the most populated cluster and shown from 4.6 (1)(representative 
structure of most populated cluster from 0 to 5 ns) to (4) (representative structure of 
most populated cluster from 15 to 20 ns). The amino acids that are most common in 
hydrogen bond interactions are explicitly labeled 
 
The frequency of the specific pharmacophore features and the interaction map for 
2OJ9 are shown in Fig. 4.7. 
The initial pharmacophore hypothesis (shown in Fig. 4.7 A) includes 5 
pharmacophore features (which will be called PDB features) and during the MD 
simulation 6 additional pharmacophore features (3 aromatic features, 1 hydrogen 
bond acceptor and 2 hydrogen bond donor features) are revealed (which will be 
called MD derived features). 
As can be seen in Fig. 4.7 A, most of the MD derived pharmacophore features have a 
lower statistical frequency than the PDB features – only the MD derived feature 
HBD1 occurs more often than HBD3 or HBA2 (both are PDB features). A further 
observation that can be drawn from Fig. 1A is that hydrophobic features are far more 
stable during the MD simulation than hydrogen bond features and that aromatic 
features are the most unstable feature type. This finding is in accordance to our 
previous findings reported in [143]. 
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Figure 4.7. Analysis of the dynamics of the pharmacophore features of 2OJ9. (A) 
shows a 2D representation of the ligand with the pharmacophore features mapped 
on the structure. Yellow spheres represent hydrophobic (H) interactions, small green 
circles indicate hydrogen bond donor (HBD) features and small red circles hydrogen 
bond acceptor (HBA) features. Black and white chess-fields represent aromatic 
features (AR). For every feature a box is shown, providing the feature name that is 
used in part (B) and (C) of the figure and information about the statistical frequency 
(given in percent and rounded to integers) of the specific feature. Dashed outlined 
boxes indicate features that are not present in the PDB pharmacophore, continuous 
lined boxes indicate features that are present in the PDB pharmacophore. The color 
of the boxes are consistent with the colored row labels in part (B) and the colored 
lines in part (C) of the figure. (B) shows the interaction matrix as heat-map. The row 
names indicate the pharmacophore features and the column names the interaction 
partners of the pharmacophore features. The column names consist of three parts, 
separated by underscores: the first part indicates the feature type, the second part 
the 3-letter amino acid code and the third part the residue number of the amino acid. 
The entries in the interaction map are color coded, ranging from dark blue to dark 
red (as shown in the legend of Fig. B.). The absolute values of the cells in the 
interaction map are written as numbers for all feature types other than hydrophobic 
features if the number of interaction is below 400. (C) shows the statistical frequency 
of the features as a function of time. Thick enclosing lines indicate pharmacophore 
features that were present in the pharmacophore model obtained with the PDB 
structure, whereas thin, dashed lines indicate features that are not present in the 
PDB structure. The Y-axis corresponds to the number of occurrences of the specific 
feature per binned time-step and the X-axis corresponds to the binned time-steps. 
For a detailed description of this plot see the Methods Section, 'Frequency Plot 
generation'.  
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A closer look at Fig. 4.7 B reveals why most hydrophobic features have such stable 
and high frequencies – they interact with multiple interaction partners at the same 
time, thus preserving the interaction even in the case that one interaction partner 
leaves the range of influence of the ligand. It should be noted that the presented 
hydrogen bond features also have multiple interaction partners, but, indicated by the 
numbers for the different interaction partners for the hydrogen bond features, this 
feature type changes rarely between them, and if so, the change is slow and 
infrequent. 
Fig. 4.7 C shows additional time resolved information about the frequencies of the 
pharmacophore features. As can be seen, the three hydrophobic features occur 
steadily above 95% for all binned time-steps – with the exception of H1 between the 
binned time-step 5 and 8. Around the same binned-time steps the frequency of HBA2 
and HBD3 (both PDB features) drops and HBD1 (MD derived feature) appears with 
a subsequent frequency of around 70%. The high frequency of HBD1 is only partly 
represented in the total frequency (as seen in Fig. 4.7 A), since the feature was not 
present for the first quarter of the simulation. Our analysis provides an explanation 
for what happens at these binned time-steps. The RMSD value of the ligand starts to 
rise (shown in Fig. 4.6) and the movement of the ligand results in a change of the 
presented interaction partner, therefor we observe the drop in the frequencies for 
HBD3 and HBA2. The data presented in Fig. 4.7, especially in Fig. 4.7C, suggest, 
that the pharmacophore model which is appropriate for the first quarter of the 
simulation (based on the frequencies of the features) does not represent the second 
half of the simulation. Considering the different frequencies of the pharmacophore 
features two pharmacophore models are proposed: The first model contains the three 
hydrophobic features and HBD3 and HBA2 – this is the pharmacophore model 
derived from the PDB structure (and will be called subsequently PDB 
pharmacophore model). The second pharmacophore model contains the three 
hydrophobic features but HBA2 and HBD3 are exchanged in favor of HBD1 and 
HBD2 (and this model will be called MD derived pharmacophore model). These two 
pharmacophore models represent the pharmacophore features with different 
frequencies in the beginning and at the end of the MD simulation. Especially in the 
light of the work in [166], the reported findings are interesting. Although in the 
presented study a different tautomer was used than in [166], the typical hydrogen 
pattern with MET103 and GLU101 is present. But it appears as if the interaction 
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with LEU26 and ASP107 (as shown in Fig. 4.7 B) can also play an important role. In 
the following section the virtual screening results with these two pharmacophore 
models against a library of known actives and calculated decoys will be shown and 
discussed in detail. 
 
The screening results (the receiver operator curve, enrichment factor and number of 
total hits) for the different pharmacophore models are shown in Fig. 4.8 Both 
pharmacophore models are able to discriminate between actives and decoys, and thus 
both provide good early enrichment. 
The PDB pharmacophore model gives rise to 81 hits and the enrichment factor at 
1.5% is 24.7. The pharmacophore hypothesis is able to retrieve 45 of the 226 active 
compounds. 
The MD derived pharmacophore model leads to 530 hits, the early enrichment factor 
at 1.5% is 6.2. The pharmacophore model retrieves 66 of the 226 active compounds 
in the library. 
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Figure 4.8. The receiver operating characteristic (ROC) curves and the two 
pharmacophore models are shown. In the ROC curve the true positive rate on the Y 
axis is plotted against the false positive rate on the X axis. The number of total hits 
and the enrichment factor (EF) are shown at 1%, 5%, 10% and 100%, respectively. 
In (A) the pharmacophore model obtained with the PDB structure and the virtual 
screening results are shown. In (B) the pharmacophore models with two MD derived 
hydrogen bond donor features and the virtual screening results are shown. For the 
description of the graphical 2D representation of the pharmacophore features see 
legend of Fig. 4.7. 
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A closer look at the hit-list obtained with both pharmacophore models reveals that 
the PDB pharmacophore model retrieves 33 active molecules that are not present in 
the hit-list obtained with the MD derived pharmacophore model. The MD derived 
pharmacophore model retrieves 54 unique hits – the hit-list of both pharmacophore 
models share only 12 active molecules. This is not surprising since the 
pharmacophore models are different and represent two distinct interaction modes.  
These two pharmacophore models can be used together – the PDB pharmacophore 
model is more likely able to distinguish between active and decoy models, but the 
MD derived pharmacophore model correctly identifies a higher number of active 
molecules. Since both models share only 12 active molecules in the resulting hit list, 
combining the results of these models results in a higher number of active candidates 
than only using the PDB pharmacophore. 
 
4.3.4 Conclusions  
!
In conclusion, MD simulations can reveal otherwise hidden pharmacophore features 
that are not present in the pharmacophore model derived from the experimental 
crystal structure. Using additional information obtained from MD simulation, i.e. 
time resolved frequency information and interaction plots, it is possible to construct 
pharmacophore models that integrate the dynamic of the ligand inside of the binding 
pocket. Furthermore, this approach provides an objective way to add MD derived 
pharmacophore features to PDB derived pharmacophore models or, on the other side, 
remove PDB features that are less important based on the observed frequencies. 
!
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4.4 A dynamic–shared Pharmacophore approach to 
improve early enrichment in virtual screening.  
A case study on PPAR alpha 
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4.4.1 Introduction  
!
Analysing the interaction pattern of ligands with a specific protein target has a strong 
bias towards the molecular structure of the ligand. Proteins can interact with active 
ligands of diverse shape, size and composition – which is not surprising since 
binding is a dynamic equilibrium process and the conformation of the binding site 
can be strongly influenced by the shape of the molecular binder [49]. But these 
findings raise doubts about the usefulness of the interaction pattern of one particular 
active binder as sole starting point for further drug discovery approaches. This issue 
can be avoided if the interaction patterns of multiple ligands are regarded for model 
development and refinement. In two recent papers [142, 143] we have shown how 
the information gained in the course of MD simulation can be combined with 
pharmacophore modelling. However, in this chapter we followed a different 
approach: to develop a workflow that addresses the arising issues of molecular 
docking and pharmacophore modelling when using (1) a single set of coordinates 
and (2) a single active ligand. 
The starting point of this new approach are the crystal structures of three different 
ligands co-crystallised with the same protein (PDB CODE: 2P54, 4CI4, 3VI8) [93]. 
MD simulations are carried out for each of the structures, ligand-target interactions 
are analysed and finally modelled as pharmacophore features. A pharmacophore 
model is constructed using only the common pharmacophoric feature patterns that all 
three ligands exhibit during MD simulations. This ‘Molecular dYnamics SHAred 
PharmacophorE’ (MYSHAPE) is subsequently used for virtual screening using 
active and inactive molecules. The virtual screening performance of molecular 
docking is improved by adding constraints to the docking grid. These constraints 
reflect the pharmacophore feature interaction pattern obtained from the analysis of 
the MD simulation data. A consensus score based on the docking score and the 
pharmacophore alignment score is adopted at the end to maximize the virtual 
screening performance. In order to validate the approach, the virtual screening results 
of the different pharmacophore models and molecular docking runs are analysed. In 
other words, the screening results of the MYSHAPE model and the pharmacophore 
models obtained using the crystal structures are compared as well as the docking 
results using the crystal coordinate set with or without constraints. For the validation 
of the screening results Receiver-Operator Characteristics (ROC) graphs were 
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generated and then the Area Under the ROC Curve (ROC-AUC) is calculated. In 
particular, the focus is on the early enrichment of the resulting hit-list. The screening 
database contained molecules obtained from the DUD-E database for this target and 
was further enriched with ligands from the ChEMBL [168] and ZINC [169] 
databases. 
 
4.4.2 Materials and Methods !
 
System quality assessment and protein preparation 
The selection of the investigated systems was based on the following criteria: high 
resolution of the crystal structure (below 2.5 Å), no metal ions in the binding pocket 
and only one bound ligand in the PDB structure. The electron density (ED) was 
evaluated using VHELIBS [33]. The protein preparation wizard [170] provided in 
MAESTRO 10.2 was used to add bond orders and hydrogens to the crystal structure. 
Subsequently Prime 4.0 [171, 172] was  used to fix missing residues or atoms in the 
protein and to remove co-crystallised water. The protonation state of the protein and 
the ligand were evaluated using PropKa 3.1 [156, 157].  
Molecular Dynamics 
For every protein-ligand complex three 20 ns molecular dynamics simulations were 
performed. For each of the three simulations the same coordinate sets but different 
initial velocities were used. The MD simulations were performed with DESMOND 
4.2 using the OPLS3 force field [173–175]. The complexes were solvated in 
orthorhombic boxes using the TIP3P water model. Ions were added to neutralize 
charges. The systems were minimised and equilibrated at a temperature of 303.15 K 
and at 1.013 bar pressure. The system was simulated as NPT ensemble, using a 
Nose-Hover thermostat and a Martyna-Tobia-Klein barostat. The integration time 
step was chosen to be 2 fs. In order to keep the hydrogen - heavy atom bonds rigid, 
the SHAKE algorithm was utilized. A 9 Å cut-off radius was set for the short range 
Coulomb interactions and smooth particle mesh Ewald was used for the long range 
interactions. The stability of systems was evaluated using the root mean square 
deviation (RMSD) of the aligned protein and ligand coordinate set calculated from 
the initial frame. 
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Shared features evaluation 
The presence of pharmacophore features and their frequency during the MD 
simulation was investigated using the Interaction diagram tool provided by Maestro 
10.2. A pharmacophore model based on the MD derived common features was then 
created considering only the common interactions that were found for the ligands in 
all MD simulations. In the following, the term MYSHAPE will be used to 
distinguish this type of model from the ‘default’ pharmacophore models generated 
using the crystal structure of the ligand-protein complex. 
MYSHAPE model pharmacophore generation 
In order to construct the MYSHAPE, the following workflow was applied: the 
different PDB protein-ligand structures were imported into LigandScout [20, 176] 
and for each complex a structure-based pharmacophore model was generated. 
Subsequently a shared pharmacophore model was generated using the structure-
based pharmacophore models. Pharmacophore features, occurring during the MD 
simulation but not present in the original shared pharmacophore model, were added 
to the shared model. For the newly added pharmacophore features the tolerance 
radius was increased by 0.15 Å in order to compensate for small deviations in the 3D 
coordinates. 
Docking Grid generation 
Using the pharmacophore interaction pattern obtained from the MD simulations 
constraints were set on the docking grid. Specifically, positional constraints were 
imposed considering aromatic interactions, hydrogen bonds and hydrophobic 
interactions with the ligand according to the GLIDE grid constraints panel workflow. 
For each analysed protein-ligand system a docking grid with and without constraints 
was generated. 
Ligand selection and preparation 
In order to validate the virtual screening performance of the pharmacophore models 
and the docking grids, databases with known active and inactive compounds were 
generated. Using compounds with known activity makes it possible to test the 
capability of pharmacophore models and docking approaches to differentiate 
between active compounds and inactive molecules - which is the ultimate goal of 
both methods. To generate the screening library, active and decoy compounds were 
retrieved from the DUD-E database [151] and filtered to remove duplicates. The 
final data set contained 373 active and 5810 decoy molecules. The active and decoy 
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molecules were then optimised utilizing the Ligprep plugin provided by the 
MAESTRO software. The OPLS3 [175] force field was chosen and the protonation 
state of ligand set in accordance to a pH value equal to 7. 
Pharmacophore screening 
LigandScout [176] was used to perform the virtual screening analysis for the 
generated pharmacophore models. Standard settings were used as described in the 
user manual [176]. Receiver Operating Characteristics (ROC) graphs were generated 
and the Area Under the Curve (AUC) as well as the enrichment factor (EF) was 
calculated to validate the virtual screening performance of the pharmacophore 
models. For the 3VI8 PDB system we interpolated the four pyrene hydrophobic 
features into two and increase the tolerance of 0.30 Å, to avoid screening results with 
0 hits. This resulted in a more sensitive model that also presented the same number 
of features than the others, allowing an easier comparison. 
Molecular Docking Screening 
Standard Precision (SP) and Extra Precision (XP) molecular docking with and 
without constraints was performed using GLIDE [94–96]. Ligands were considered 
flexible and EpiK state penalties were added to the docking score. ROC graphs and 
Robust Initial Enrichment (RIE) [177–179] were used to evaluate the virtual 
screening capability of the docking runs. In contrast to pharmacophore modelling the 
AUC was not calculated for different fractions of the screening database but a 
numeric representation of the Receiver Operator Characteristic area underneath the 
curve was obtained. This ROC value can be interpreted as the probability that an 
active will appear before an inactive compound and is calculated as follows (eq. 4.2): 
 
         eq.4.2 
where AUAC is the area under the accumulation curve, 
Ri is the ratio of inactive molecules s to the total number of compounds 
in the screening library 
Ra is the ratio of active compounds to the total number of entries in the 
screening library. 
 
The RIE and the ROC value were generated using the “enrichment calculator” 
python script provided by Schrodinger. The EF was not calculated because the 
different docking runs produce ranked lists with different lengths and the EF is 
affected by the length of the datasets. 
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Pharmacophore alignment and ranking of docked conformations of ligands 
For the protein-ligand system that performed best in molecular docking the resulting 
molecule list was imported into LigandScout [20, 176] and pharmacophore scores 
were calculated for each compound. This was done in order to compare the ranking 
of molecular docking with the one of pharmacophore modelling. The different 
rankings were evaluated using the EF at different percentages of the screening 
dataset with particular attention to the early enrichment [177, 178]. 
Post-processing Consensus Score 
Furthermore, for the best performing system a consensus score was calculated that 
combined the pharmacophore and docking score as shown in Equation (4.3). 
 
     eq.4.3  
 
Evaluation of the chemotype enrichment 
For checking the similarity of the compounds in the hit-lists of the pharmacophore 
models a KNIME workflow [180] was created that used the Morgan fingerprinting 
functionality of RDkit [86]. The chemotype similarity was evaluated using a 2D 
fingerprints (Morgan/Circular) [181]. Tanimoto distances of the fingerprints were 
calculated and K-medoids clustering was performed [182] (setting K =5) in order to 
analyze the distribution of chemotypes in the actives library. For the K-medoids 
search and clustering, no constraints were applied to the iterations. This means that 
the search for medoids and then the population of the clusters was stopped only when 
the best result was reached or no better solution was available. The protocol was 
applied on the whole active set and on the first 100 actives retrieved by the screening 
runs, to check if the model was capable to discriminate only one type of molecules or 
if the heterogeneity of the actives molecules was maintained in the early recognised 
ones.  
 
4.4.3 Results and Discussion 
!
Molecular dynamics 
For the MD simulations the RMSD of the protein and ligand was calculated as 
described in the Methods Section. The protein and ligand showed normal RMSD 
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values over the course of the 20 ns of simulation and no large scale movement could 
be observed.  
Shared features evaluation 
As described in the Methods section, the interactions between the ligand and protein 
were investigated and a common interaction pattern was compiled. Figure 4.9 shows 
the protein-ligand interactions of the three different ligands. In such figure, the 
interactions that were used to construct the MYSHAPE model are highlighted. 
(shown in Figure 4.9). 
One of the most interesting interaction event is the aromatic feature that only appears 
during the MD simulation. Remarkably, no pharmacophore model constructed from 
the crystal structure presents such pharmacophore feature. Moreover, without MD 
simulations this feature would have remained hidden. The common interaction 
pattern derived from the MD simulation of the different protein-ligand complexes 
consists of two hydrogen-bond acceptors, three hydrophobic interactions and one 
aromatic interaction (as shown in Figure 1). Four of these pharmacophore features 
are in all ligands associated with the same chemical group - the two hydrogen-bond 
acceptors are always located at a carboxyl group and the aromatic and one 
hydrophobic feature are always located at a central phenyl ring. The remaining two 
hydrophobic features are located at similar chemical groups but not at the same in all 
three ligands.  
 
 
! 83!
 
 
Fig.4.9 The three different ligands of 2P54, 3VI8 and 4CI4 are shown. The common 
features retrieved from the MD simulations are depicted on the ligands as coloured 
spheres. Red spheres indicate hydrogen-bond acceptor features, yellow spheres 
represent hydrophobic interactions and the blue ring represents an aromatic 
interaction. This common interaction pattern was used to generate a shared 
interaction. 
 
Pharmacophore screening and Pharmacophore alignment score 
The virtual screening performance of the four different pharmacophore models was 
investigated using a screening library composed of molecules with known activity as 
described above. Figure4.10 shows the three pharmacophore models that were 
created using the crystal structure, the generated MD derived common feature 
pharmacophore model and their virtual screening performance.  
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Fig.4.10 Pharmacophore models with ligands and related ROC curve derived 
metrics for the pharmacophore screening of the three PDB structures and the MD-
MRC derived one. For the MD-MRC model, best ranked molecule has been used. 
AUC is refers to the entire screened dataset; the EF is calculated for the hit-list with 
retrieved molecules. Red spheres = hydrogen-bond acceptor, Green spheres = 
hydrogen-bond donor, Yellow spheres = hydrophobic feature, Blue ring = aromatic 
feature. 
 
In Figure 4.11, the ROC graphs are reported for each system. Virtual screening 
results were evaluated using the ROC-AUC values for 1%, 5%,10% and 100% of the 
screening database and calculating the enrichment factors for 1%, 5%, 10% and 
100%. A closer look at the ROC-AUC values for the four models (MYSHAPE 
model, 2P54 pharmacophore model, 3VI8 pharmacophore model and 4CI4 
pharmacophore model) shows that all models perform well for 1% and 5%. The three 
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pharmacophore models retrieve hit lists with a relatively low number of hits (5, 14 
and 26) compared to the results of the MYSHAPE model (61 hits).  
The number of hits heavily influences the EF calculation. For this reason, the ROC-
AUC value is a better metric to judge the performance of virtual screening runs that 
return hit-lists with different number of compounds. 
 
Fig.4.11 The ROC graphs for each model –pharmacophore screening 
 
The calculated ROC-AUC values from the hit-list of the MYSHAPE model are 1 
(1%), 0.99 (5%), 0.93 (10%) and 0.54 (100%). Comparing these values with the 
screening performance of the default pharmacophore models obtained from the 
crystal structure show that the MD derived common feature pharmacophore model 
has a better enrichment with active compounds than all other models. 4CI4 is the 
only model that retrieves for 1% of the screening database the same number of active 
compounds, but for 5% the ROC-AUC value is lower than the ROC-AUC calculated 
from the hit-list obtained with the MYSHAPE model. 
Docking Process 
As described in the Methods section docking grids were constructed for the three 
different investigated protein-ligand systems - either with constraints derived from 
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the MD simulations or without constraints. As a first approach SP docking was used 
to analyze the change in virtual screening capability of using grids with constraints. 
As a metric ROC graph values and RIE were used. The results are shown in Figure 
4.12. 
 
Fig.4.12 ROC curves and metrics for the SP docking on the three analysed system 
 
The SP docking performs well for all investigated systems. As can be seen from the 
ROC graphs for all three systems the SP docking favours active molecules over 
inactive compounds. The ROC graph for 2P54 shows the best virtual screening 
performance of the systems. For all the studied systems one can conclude that the 
usage of constraints in the docking grid improves the virtual screening capability. 
After the SP docking analysis we decided to proceed only with the 2P54 and submit 
it to the XP docking process trying to further improve the screening capability of our 
protocol. 
In Figure 4.13 the results obtained from the XP docking runs with and without grid 
constraints are reported. As demonstrated by both XP curves and metrics, the 
application of grid constraints has not a high impact on the XP docking protocol. 
Moreover, comparing the ROC curve of the XP docking run with the one of the SP 
run with constraints, it seems that there is only a small increase in the capability of 
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the model. On the other hand, the application of constraints seems to reduce a little 
bit the sensitivity of the model, possibly because the combination of the XP 
algorithm with the constraints is too strict for the retrieval of molecules. 
 
Fig.4.13 ROC curves and metrics for the 2P54 system after XP docking 
 
Pharmacophore alignment and score of the docked conformations 
We wanted then to test the capability of the MD derived common feature 
pharmacophore model to correctly rank actives and decoys. In the following tables 
we compare the EF of the hit-list molecules ranked by XP docking score (with and 
without constraints) with the EF of the hit-list ranked by the pharmacophore 
alignment score of the docked conformations. 
 
Tab.4.3. EF for the two XP docking processes compared with the Pharmacophore 
score applied to docked conformations. 
 
 
As the table 4.3 shows, it seems that the ranking of the molecules is better using the 
docking score than the pharmacophore score, showing a slight decrease of the 
screening capability in early enrichment. 
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However, it was interesting to see that the ranking produced by the two methods is 
quite different. The early enrichment produced by the two scoring models thus leads 
to different sets of molecules. For this reason, we decided to merge the two scoring 
functions into a consensus score. 
Consensus Score 
Starting from docking and pharmacophore alignment scores, we ranked the dataset 
with the consensus score described earlier in the Materials and Methods section (Eq. 
2). We observed an interesting increase in early enrichment, with and without 
constraints. The consensus score was able to maintain the maximum EF at the 1% of 
the ranked list, and improved the general trend of the screening process until the 2% 
for the docked conformations without constraints and to the 5% for the ones docked 
with constraints. (table 4.4). 
 
Tab.4.4. EF for the two XP docking processes compared with the consensus score 
applied to docked conformations. 
 
 
Evaluation of the chemotype enrichment 
Finally, we checked the presence of possible biases in the whole protocol towards a 
unique chemotype of active molecules. As described in the Methods section, the 
calculation of distance matrix and k-medoids clustering based on Morgan 
fingerprints was used to check the chemotype distribution of active compounds. In 
Table 4.5 we report the medoid molecules of each cluster formed by the K-medoids 
algorithm, whereas in the table 4.6 are reported the distribution of active molecules 
for each cluster found. Values are expressed as percentage. 
As shown by the results in table 4.5, the model adopted is able to rank all the 
different chemotypes found in the actives set. 
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Tab.4.5. Medoid molecules for each cluster formed 
 
 
Tab.4.6. Distribution of active molecules in the 5 cluster created 
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4.4.4 Conclusions!
 
We have presented a new virtual screening workflow that addresses the arising issues 
of molecular docking and pharmacophore modelling when using a single set of 
coordinates and a single active ligand. The starting point of our study were three 
crystal structures of the PPARα receptor containing different ligands co-crystallised 
with the same protein (PDB CODE: 2P54, 4CI4, 3VI8) [30]. For each structure, MD 
simulations were carried out and ligand-protein interactions were analysed and 
collected together with their appearance frequency. A pharmacophore model was 
then created using only the common feature patterns that all three ligands exhibited 
during MD simulations. This ‘Molecular dYnamics SHAred PharmacophorE’ 
(MYSHAPE) was then used for virtual screening on active and inactive molecules 
library. SHAPE was also used as constraints for the creation of the docking grid. 
This approach contributed to a rise in the molecular docking virtual screening 
performance. Finally, a consensus score based on the docking score and the 
pharmacophore alignment score was adopted to maximise the virtual screening 
performance. In order to validate the approach, we compared the virtual screening 
results of the different pharmacophore models and molecular docking runs. The aim 
of the work was the comparison between the screening performance of the shared 
feature pharmacophore and the pharmacophore models obtained using the crystal 
structures as well as the docking results using the crystal coordinate set with or 
without constraints. 
The application of the MYSHAPE model showed an interesting increase of the 
screening capability both in terms of sensitivity of the model and specificity when 
compared to the three PDB models. The use of these interaction patterns to create the 
docking grid showed an improvement in the early recognition of actives compounds, 
especially for one of the three systems (4CI4) where the Robust Initial Enrichment 
(RIE) passed from 3.45 to 6.1. At first sight, the application of constraints at the XP 
docking protocol does not seem to strongly influence the docking protocol capability, 
probably because of the high precision of the XP docking algorithm itself that avoids 
high false positives rate. Nevertheless, when MYSHAPE pharmacophore model was 
used for the alignment of molecules in the docked conformation, the screening 
capability did not increase in both cases (with and without constraints). Anyway, 
adopting only the docking score or the pharmacophore score, the Enrichment Factor 
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(EF) of the protocol was good, but improvable especially for the early enrichment. 
When the two scoring methods were then combined in a consensus score there was 
an interesting boost of the virtual screening capability rising the value of the EF to be 
maximised in both docking methods. The early recognition was however improved 
until the 2% of the ranked list for the docked conformation without constraints 
whereas it was boosted until the 5% of the screening list for the docked conformation 
of molecules with constraints. The results obtained using the consensus score on the 
XP without constraints is to consider as the best compromise of speediness and 
accuracy in the virtual screening process.  
This work is a first assay for a workflow that should be applied to different proteins. 
The strength behind the protocol is the ease of use related to the improvement of 
results. It also could represent a valid alternative to the use of very time consuming 
techniques such as XP docking with constraints. The increase of prediction reliability 
could be in fact reached through the use of pharmacophores, a fast and effective tool 
combined with no-constraints docking. This approach also represents a possible 
guide to consider or to discard some of the pharmacophore features retrieved from 
the static PDB crystal structures. Moreover, the MD simulations using more crystal 
structures of the same protein but with different ligands, is an interesting approach to 
retrieve some crucial interaction features that could be missed by the use of a single 
crystal structure. In the next months this approach will be applied to other receptors 
(ER, FXR, RXR, MapKinase and others) in order to test the application of the 
approach to other proteins.  
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5! COMPUTATIONAL CHEMISTRY IN 
POLYPHARMACOLOGY AND DRUG REPURPOSING  
!
During my PhD, I had the opportunity to deeply study the possible applications of 
computational methods to drug repurposing and polypharmacology. From this 
applied study, two reviews have been published in the last year: Here I just report the 
abstract of the two published reviews [183, 184].  
 
5.1 The repurposing of old drugs or unsuccessful lead compounds by in silico 
approaches: new advances and perspectives. 
 
Abstract 
Have you a compound in your lab, which was not successful against the designed 
target, or a drug that is no more attractive? The drug repurposing represents the right 
way to reconsider them. It can be defined as the modern and rationale approach of 
the traditional methods adopted in drug discovery, based on the knowledge, insight 
and luck, alias known as serendipity. This repurposing approach can be applied both 
in silico and in wet. In this review we report the molecular modeling facilities that 
can be of huge support in the repurposing of drugs and/or unsuccessful lead 
compounds. In the last decades, different methods were proposed to help the 
scientists in drug design and in drug repurposing. The steps strongly depend on the 
approach applied. It could be a ligand or a structure based method, correlated to the 
use of specific means. These processes, starting from a compound with potential 
therapeutic properties and a sizeable number of toxicity passed tests, can successfully 
speed up the very slow development of a molecule from bench to market. Herein, we 
discuss the facilities available to date, classifying them by methods and types. We 
have reported a series of databases, ligand and structure stand-alone software, and of 
web-based tools, which are free accessible to scientific community. This review does 
not claim to be exhaustive, but can be of interest to help in drug repurposing through 
in silico methods, as a valuable tool for the medicinal chemistry community.  
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5.2 Drugs polypharmacology by in silico methods: new opportunities in drug 
discovery.  
 
Abstract 
Polypharmacology, defined as the modulation of multiple proteins rather than a 
single target to achieve a desired therapeutic effect, has been gaining increasing 
attention since 1990s, when industries had to withdraw several drugs due to their 
adverse effects, leading to permanent injuries or death, with multi-billiondollar legal 
damages. Therefore, if up to then the "one drug one target" paradigm had seen many 
researchers interest focused on the identification of selective drugs, with the strong 
expectation to avoid adverse drug reactions (ADRs), very recently new research 
strategies resulted more appealing even as attempts to overcome the decline in 
productivity of the drug discovery industry. 
Polypharmacology consists of two different approaches: the former, concerning a 
single drug interacting with multiple targets related to only one disease pathway; the 
latter, foresees a single drug's action on multiple targets involved in multiple disease 
pathways. Both new approaches are strictly connected to the discovery of new 
feasible off targets for approved drugs. 
In this review, we describe how the in silico facilities can be a crucial support in the 
design of polypharmacological drug. The traditional computational protocols (ligand 
based and structure based) can be used in the search and optimization of drugs, by 
using specific filters to address them against the polypharmacology (fingerprints, 
similarity, etc.). Moreover, we dedicated a paragraph to biological and chemical 
databases, due to their crucial role in polypharmacology. Multitarget activities 
provide the basis for drug repurposing, a slightly different issue of high interest as 
well, which is mostly applied on a single target involved in more than one diseases. 
In this contest, computational methods have raised high interest due to the reached 
power of hardware and software in the manipulation of data. 
 
!
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Assessment of the quality of the PhD Thesis “Development and optimisation of 
computational tools for drug discovery” presented by the candidate Ugo Perricone 
 
The main focus of the current thesis was the development and application of novel methods 
for computer assisted ligand design. A couple of novel methods were developed and were 
tested using data sets from literature. Good screening results could be obtained by the 
developed tools. Especially the testing of pharmacophore models derived from trajectories 
of molecular dynamics simulations (Chapter 4) represents a highly interesting part of the 
thesis. The dynamic pharmacophore models outperformed traditional pharmacophore 
models for the selected training sets. Further evaluations tests will show the general 
applicability and performance of dynamic pharmacophore models. 
 
The thesis starts with a short introduction to the field of computer assisted design 
apporoaches and pharmacophore modeling. The introduction is clearly written and shows 
the deep scientific knowledge of Ugo Perricone. The references included contain all relevant 
publications in the field.  
 
The thesis is of very good presentation and style, and shows evidence of the student’s ability 
to investigate critically a specific field of study, demonstrating an adequate knowledge and 
discussion of the literature in that field. 
 
The thesis of Ugo Perricone generated significant new knowledge in the development and 
application of dynamic pharmacophore models. Several approaches have been applied to 
different targets and novel hypothesis were obtained. A minor criticism is the not always 
clearly defined own contribution of the candidate. As it is clear that all application work has 
been done by him, this is not always clear in the other disciplines, such as programming. A 
clear statement at the beginning of the individual chapters would have been helpful. 
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It must also be stated that some parts of Ugo Perricone’s work is published in very good 
journals and I am confident that other parts of this PhD work will result in high impact 
papers. 
 
The scientific value of her work is further demonstrated by the number of already published 
manuscripts and the novel molecules optimized by chemical synthesis and structure-based 
design. Based on the overall scientific value of the material, I can confirm the high scientific 
quality of the work. In summary, I can confirm that the candidate’s contribution to the 
research and publications is sufficiently large to award him with PhD (Doctor Europaeus). 
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To Whom It May Concern 
 
 
Report on the Thesis document by Mr Ugo Perricone  
 
Mr Ugo Perricone has submitted a thesis dissertation entitled "Development and optimisation of 
computational tools for drug discovery" to Università di Palermo, as an application to obtain the academic 
degree "PhD" from their appropriate PhD program. The study was performed under the supervision of Prof. 
Anna Maria Almerico.  
 
The thesis manuscript is divided into three major chapters, together with an excellent preface provided as a sort 
of introduction to the field. All the results presented in these chapters are published in top tier, high quality 
international scientific journals with strict peer review and high impact.     
 
In the preface, Mr Perricone provides the aim of the thesis and gives an overview on the state of the art of 
computational methods in modern drug design. Tools for virtual screening (VS), such as docking, and 
pharmacophore based approaches are one focus, as well as refinement of structures using molecular dynamics 
(MD) simulations in order to be able to rank compounds based on correctly predicted binding affinities. In this 
preface, Mr Perricone gives the rational for the approaches used later during his studies, and also for the targets 
chosen as proof of principle, in order to identify new bio-active compounds interacting with proteins of 
therapeutic potential. 
 
In particular, the first chapter of the thesis, CHEMOMETRIC PROTOCOLS IN DRUG DISCOVERY, Mr 
Perricone reports on the development and enhancement of a VS protocol calculating 3D molecular descriptors 
on the docked conformation of ligands. The so-called VLKA method was used and then further enhanced to the 
Conf-VLKA approach to predict the possible biological target for new molecules starting from the structural 
information contained in molecular descriptors calculated on a set of known inhibitors. Results of this part are 
published in the article Conf-VLKA: A structure-based revisitation of the Virtual Lock-and-key Approach in J. Mol 
Graph. Model. 2017, 71, 50-57.  
 
In the second chapter, THE APPLICATION OF MOLECULAR DYNAMICS TO VIRTUAL SCREENING   Mr 
Perricone describes the efforts towards integration of pharmacophore approaches for the analysis of molecular 
dynamics trajectories. The first paper in this context, Evaluating the stability of pharmacophore features using  
 
 
  
 
molecular dynamics simulations, published in Biochem. Biophys. Res. Comm. 2016, 470, 
685-689, indicates that the frequency information obtained from the MD simulations can be used to refine the 
pharmacophore model by adding or removing features and weighting their importance. In the paper Comparing 
pharmacophore models derived from crystal structures and from molecular dynamics simulations published in 
Monatsh. Chem. 2016, 147, 553-563, Perricone and co-authors suggest that even very simple structure 
refinement approaches, like the ones reported in their study, can lead to pharmacophore models that perform 
significantly better in virtual screening. In this chapter, two more application case studies are described in the 
target areas of PPAR alpha and the IGF-1R kinase domain. Also here, Mr. Perricone can demonstrate the 
advantage of combining molecular dynamics with pharmacophore methods for optimizing the performance of 
the experiments.  
 
Finally, in the third chapter, COMPUTATIONAL CHEMISTRY IN POLYPHARMACOLOGY AND DRUG 
REPURPOSING, Mr. Perricone investigates one of the most interesting method for finding new drug 
candidates.  Here, he studies virtual screening protocols for identifying drug polypharmacology. Finally, he 
summarizes the results published in two reviews dealing with the above mentioned topics (Curr. Pharm. Des. 
2016, 22, 3073–3081 and Curr. Top. Med. Chem. 2016, 16, 2088–2106).  
 
Overall, Mr Perricone has produced an impressive amount of data using a selection of the most advanced 
methods used in virtual screening. The results of his studies further contribute to the knowledge of compounds 
interacting with different targets since he has identified potential compounds that were shown to be active. He 
has undoubtly shown his ability to derive scientifically correct conclusions. In view of these facts, this reviewer 
suggests the grade ‘Excellent’ for the present thesis. Clearly, he is in addition eligible for the international Doctor 
Europaeus title. 
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